

Curriculum Vitae

March 27, 2024

PERSONAL INFORMATION

Name: **Marisa B. Marques, MD**
Citizenship: United States, Brazil
Foreign Languages: Portuguese, Spanish

RANK/TITLE: Professor Emerita of Pathology
Business Address: The University of Alabama at Birmingham (UAB)
619 South 19th Street, WP P220C
Birmingham, Alabama 35249-7331
Phone: (205) 934-6421
Fax: (205) 975-4468
Email: mmarques@uabmc.edu

HOSPITAL AND OTHER (NON-ACADEMIC) APPOINTMENTS:

March 1999-July 2015	Section Head, Hemostasis, Division of Laboratory Medicine, UAB
April 2001 – July 2015	Medical Director, UAB Coagulation Service, Division of Laboratory Medicine, UAB
July 2003 – June 2004	Interim Section Head, Transfusion Medicine Services, Division of Laboratory Medicine, UAB
October 2003-June 2015	Consultant, Veterans Administration Medical Center, Pathology & Laboratory Medicine Service, Birmingham, AL
July 2004 – June 2023	Section Head, Transfusion Medicine Section, Division of Laboratory Medicine, UAB
February 2006 – August 2018	Laboratory Director, Anesthesia/CICU laboratory, UAB
October 2013-February 2015	Medical Director, Blood Bank, Baptist Health System hospitals, Montgomery, AL
February 2015 – August 2023	Consultant, Blood Bank, Baptist Health System hospitals, Montgomery, AL
Nov. 2014 – August 2023	Consultant, Blood Bank, Northeast RMC and affiliated hospitals, Anniston, AL
August 2017 – August 2023	Consultant in Apheresis, Children’s Hospital of Alabama, Birmingham, AL
January 2018- June 2023	Medical Director, Apheresis Collection Facility, UAB
Nov. 2018 – August 2023	Consultant, Blood Bank, Riverview RMC, Gadsden, AL
Dec. 2019 – March 2020	Associate Division Director, Division of Laboratory Medicine, Department of Pathology, UAB
April 2020 – July 2021	Interim Division Director, Division of Laboratory Medicine, Department of Pathology, UAB
July 2020 – June 2023	Laboratory Director, Callahan Eye Hospital & Clinics
July 2021 – present	Senior Scientist, UAB Center for Injury Science

Other Professional Appointments

July 2003 – June 2023 Director, Transfusion Medicine Fellowship Program, UAB
October 2006- June 2023 Medical Director, UAB Highlands Blood Bank
October 2020-August 2021 Chair, Diversity Task Force, Department of Pathology, UAB

PROFESSIONAL CONSULTANTSHIPS:

None

EDUCATION:

Institution	Degree	Year
Federal University of Rio Grande do Sul, Brazil	MD	1983

LICENSURE:

1983 Rio Grande do Sul, License Registration #13280
1983 Certified, Medical Association of Rio Grande do Sul Examination
1985 ECFMG Examinations - Certificate # 369-715-8
1986 Federal License Examination (FLEX)
1996 Alabama Medical License #19961

BOARD CERTIFICATION:

1997 Diplomate of The American Board of Pathology (ABP) in combined Anatomic and Clinical Pathology
1998 Diplomate of The American Board of Pathology in Hematology
2000 Diplomate of The American Board of Pathology in Blood Banking/Transfusion Medicine

POSTDOCTORAL TRAINING:

Year	Institution
December 1983- Dec 1985	Resident in Medicine, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil
April 1986 - June 1988	Visiting Fellow, Fogarty International, Laboratory of Clinical Investigation, NIAID, NIH, Bethesda, MD
July 1988 – March 1990	Research Fellow, Division of Infectious Disease, Beth Israel Hospital, Harvard Medical School, Boston, MA
May 1990 – June 1992	Research Fellow, Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
January 1994 – June 1997	Resident in Anatomic and Clinical Pathology, UAB
July 1997 – June 1998	Fellow in Hematopathology, UAB

April 6-11, 2003 Program for Health Care Negotiation and Conflict Resolution Leadership, Harvard School of Public Health, Boston, MA

January 20-25, 2007 Physician in Management Seminar, American College of Physician Executives, Amelia Island, FL

December 2017 Certificate in Healthcare Quality and Safety, UAB Graduate School Birmingham, AL

ACADEMIC APPOINTMENTS: (In reverse chronological order)

Year	Rank/Title	Institution
September 2023-present	Professor Emerita	UAB
October 2008 – August 2023	Professor, Division of Laboratory Medicine, Department of Pathology	UAB
October 2004 – September 2008	Associate Professor, Division of Laboratory Medicine, Department of Pathology	UAB
June 2003 - July 2008	Mentor, UAB Minority Medical Education Program	UAB School of Medicine
March 2002 – June 2008	Pathology Career Advisor	UAB School of Medicine
October 2001 – September 2004	Member, Dean’s Council for Graduate Medical Education	UAB
August 2001 – June 2007	Mentor Program	UAB School of Medicine
August 1998 – September 2004	Assistant Professor, Division of Laboratory Medicine, Department of Pathology	UAB
July 1992 – June 1993	Research Associate in Medicine	Harvard Medical School, Boston, MA
March 1983 – December 1983	Teaching Assistant, Department of Internal Medicine	Federal University of Rio Grande of Sul, Porto Alegre, RS, Brazil
March 1979 – December 1982	Teaching Assistant, Department of Biochemistry	Federal University of Rio Grande of Sul, Porto Alegre, RS, Brazil

AWARDS/HONORS:

1986-1988 Visiting Fellow, Fogarty International, Laboratory of Clinical Investigation, NIAID, NIH, Bethesda MD

1995-1996 Chief Resident in Laboratory Medicine, Department of Pathology,

UAB

1996 Paul E. Strandjord Young Investigator Award from the Academy of Clinical Laboratory Physicians and Scientists (ACLPS)

2001 Excellence in Resident Education in Clinical Pathology Award, UAB

2002 Excellence in Resident Education in Clinical Pathology Award, UAB

2002 Best Teacher Award from Hematology/Oncology fellows to non-Hematology faculty

2003 Award of Excellence for “Care” – UAB University Hospital

2005 Excellence in Resident Education in Clinical Pathology Award

2006 Argus Society Award nominee, UAB SOM

2008 Argus Society Award – Best Lecturer – Hematopathology, Class of 2009 UAB SOM

2008 Lecturer Award – American Society for Apheresis (ASFA)

2009 Argus Society Award – Best Lecturer – Hematopathology, Class of 2010 UAB SOM

2009 Argus Society Award – Best Lecturer Runner-Up – Hematopathology, Class of 2011 UAB SOM

2009 Shu T. Huang Award for Excellence in Laboratory Medicine Education, Department of Pathology, UAB

2009-2018 Best Doctors in America

2010 Argus Society Award – Best Lecturer Runner-Up – Hematopathology, Class of 2012 UAB SOM

2010 Shu T. Huang Award for Excellence in Laboratory Medicine Education, Department of Pathology, UAB

2010 Top-rated Hospital Medical Director (perfect score), UAB Hospital

2011 Becky Trigg Outstanding Woman Faculty Member UAB

2012 First Place, Innovation Award, Blood Management Program, UAB Hospital

2013 Argus Society Award – Best Lecturer Nominee – Hematopathology, Class of 2015 UAB SOM

2014 Argus Society Award – Best Lecturer Nominee – Hematopathology, Class of 2016 UAB SOM

2014 Alpha Omega Alpha Honor Medical Society, UAB

2015 Klaus Mayer Lecture in Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

2016 Inaugural Executive Section Editor of Anesthesia&Analgesia new section “Blood Management”

2017 Presidential Award – American Society for Apheresis (ASFA)

2017 Excellence in Mentorship Award – American Medical Women’s Association (AMWA)

2017 Award for Outstanding Contributions to Management Sciences and Patient Safety (MSPS) - American Association of Clinical Chemistry (AACC)

2017 Argus Society Award – Best Lecturer Nominee – Hematopathology, Class of 2019 UAB SOM

2018 Dean’s Excellence Award in Teaching, Senior Faculty, UAB SOM

2021 Professional Excellence Award, Hispanic/LATINX Faculty Association, UAB SOM

2022 Francis S. Morrison Memorial Lectureship Award, ASFA

2022 Shu T. Huang Award for Excellence in Laboratory Medicine Education, Department of Pathology, UAB

2023 Shu T. Huang Award for Excellence in Laboratory Medicine Education, Department of Pathology, UAB

PROFESSIONAL SOCIETIES:

2015-	Alpha Omega Alpha Honor Medical Society, UAB
2014-	Society for the Advancement of Blood Management (SABM)
2013-2016	American Society of Nephrology (ASN)
2010-	American Medical Women's Association (AMWA)
2004-	American Society of Hematology (ASH)
2002-2014	International Society on Thrombosis and Haemostasis (ISTH)
1999-	American Society for Apheresis (ASFA)
1998-	AABB
1996-	Academy of Clinical Laboratory Physicians and Scientists (ACLPS)
1995-2016	College of American Pathologists (CAP)
1995-	American Society for Clinical Pathology (ASCP)

MEMBERSHIPS:

See "Professional Societies"

COUNCILS AND COMMITTEES:

National

2001-2004	Nominations and Awards Committee, Academy of Clinical Laboratory Physicians and Scientists (ACLPS)
2004-2014	Education Committee, American Society for Apheresis (ASFA)
2005-2013	Clinical Applications Committee, ASFA
2005-2008	International Committee, ASFA
2006-2009	Chair, Performance Metrics Subcommittee, ASFA
2007	Co-chair, scientific program, ASFA annual meeting, Nashville, TN
2007-2012	Clinical Transfusion Medicine Committee, AABB
2007-2011	Annual Meeting Education Program Unit, AABB
2008-2010	ASFA Board of Directors - Medical Director
2008-2012	ACLPS Executive Council
2008-2018	Clinical Laboratory Integration into Healthcare Collaborative (CLIHC), CDC
2009-2012	Scientific Committee on Hematopathology and Clinical Laboratory Hematology, American Society of Hematology (ASH)
2009-present	AABB Press Editorial Board
2009-2014	Education Committee, ACLPS
2009-2011	PRISE Committee, ASCP
2010-2011	TMISE Committee, ASCP
2010-2011	Secretary, ASFA
2010-2011	ASFA Liaison to the AABB education program
2011-2012	Treasurer, ASFA
2012-2014	National Comprehensive Cancer Network (NCCN) Cancer and Chemotherapy-induced Anemia Panel Member
2012	The Joint Commission Overuse Summit member (ASCP representative)
2012-2013	Vice-President, ASFA
2012-2015	Blood Banking Examination Committee, ASCP Board of Certification
2013-2014	President-Elect, ASFA

2013-2014	Chair, Organizing Committee ASFA/WAA 2014 conference
2013-2016	Commission on Continuing Professional Development (CCPD), ASCP
2013-2015	Laboratory Medicine Best Practices (LMBP™) Expert Panel, Centers for Disease Control and Prevention (CDC)
2014-2015	President, ASFA
2015-2016	Past-President, ASFA
2015-2021	Chair, Qualification in Apheresis exam, ASCP Board of Certification
2015-2016	President-elect, ACLPS
2015-2016	Treasurer, Society for the Advancement of Blood Management (SABM)
2016-2017	President, ACLPS
2017-2018	Immediate Past-President, ACLPS
2018-2019	Past-President, ACLPS
2019-	Test Development and Advisory Committee for Blood Banking/Transfusion Medicine, American Board of Pathology (ABP)
2019-	Bylaws Committee, ASFA
2020-	FDA Blood Products Advisory Committee member
2021-	Nominating and Awards Committee, ACLPS

University

1999-2005	Department of Pathology Residency Selection Committee
2004-2008	Senator, UAB Faculty Senate
2004-2006	Member, Faculty Subcommittee, LCME Accreditation Preparation Process
2006-2007	Member, Commission on the Status of Women
2007-2008	Senator-at-large, UAB Faculty Senate

University Hospital

1998- 2003	Transfusion Medicine/Blood Bank Fellowship Committee
1998- 2003	Blood Utilization Committee, member
2001-2004	Dean's Council for Graduate Medical Education
2003-2008	Chair, Blood Utilization Committee (BUC)
2003-2010	Quality Council
2003-2023	Blood Banking/Transfusion Medicine Fellowship, Program Director
2006-2014	Critical Care Committee
2006-2010	Utilization Review Committee
2007-2018	Medical Directors Council
2008-2009	Anticoagulation Task Force
2008-2023	Chair, Blood Utilization and Management Committee (BUMC)
2012-2015	Laboratory Optimization Committee (LOC)
2013-2014	UABHS Anticoagulation Task Force
2013-2015	Cardiovascular Blood Management Task Force
2013-2015	Pharmacy & Therapeutics Committee
2016-2019	Promotion and Tenure Committee, Department of Pathology
2020-2023	Pharmacy & Therapeutics Committee – Anticoagulation Subcommittee

Health Services Foundation

2000-present "Dear Doctors" column consultant
2002-2004 HSF-GEF review committee for Medical Education Initiatives
2007-2011 Performance Improvement Patient Safety Committee
2009 Ambulatory EHR Executive Steering Team
2009 Ambulatory EHR Laboratory Orders Team Physician Sponsor

Veterans Affairs Medical Center

2003-2015 Veterans Administration Transfusion Practice Committee

Community

1998-2020 Chamber Choir, Saint Peter Catholic Church

UNIVERSITY ACTIVITIES:

Medical/ Dental School

1999-2021 Medical School Pathology Course – lecturer
1999-2001 Dental-Optometry Pathology Course – lecturer
1999-2010 Dental Clinical Pathology Graduate Course - course master
2000-2007 Medical School Pharmacology Course - lecturer
2000-2001 Dental-Optometry Pharmacology Course – lecturer
2003 Medical Student Research Day - judge
2007-2010 Scholarship Committee – University of Alabama School of Medicine (UASOM)
2008, 2009, 2011 Admissions Committee - UASOM
2008-2021 Special Topics course in Appropriate Laboratory Test Utilization, UASOM
2008-2013 Faculty Advisor, UASOM American Medical Women's Association (AMWA)
2015-2018 Admissions Committee – UASOM
2009-2012 Mentor, Scholar activity (various students)
2016-2017 Membership chair, UASOM American Medical Women's Association (AMWA)
2018 - 2023 Student Academic Standing Committee (SASC)
2019 - 2023 President, American Medical Women's Association (AMWA) UASOM chapter
2021 - 2022 Co-chair, Hispanic/Latinx Faculty Association, UASOM

EDITORIAL BOARD MEMBERSHIPS:

2002-2008 Laboratory Medicine - Editorial Advisory Board
2003-2012 American Journal of Clinical Pathology – Board of Editors
2004-2016 Journal of Clinical Apheresis – Associate Editor
2009-present American Journal of Medicine - Ad Hoc reviewer
2010-present JAMA - Ad Hoc reviewer
2010-present Clinical Chemistry - Ad Hoc reviewer
2010-present Transfusion - Ad Hoc reviewer
2013-present Vox Sanguinis – Ad Hoc reviewer
2015-2016 American Journal of Clinical Pathology –Editorial Board member
2016-2018 Anesthesia & Analgesia, Executive Section Editor, Blood Management section

MAJOR RESEARCH INTERESTS:

Patient Blood Management (PBM)
Thrombotic thrombocytopenic Purpura (TTP)
Proper Laboratory Utilization

TEACHING EXPERIENCE:

1998-present	Blood Bank Morning Report
1998-2002	Pathology Residents' Orientation
1998-2003	Introduction to Laboratory Medicine
1999-2021	Medical School Pathology Courses (2)
1999-2023	Coagulation Case Studies
1999-2023	Coagulation Curriculum
1999-2023	Transfusion Medicine Didactic sessions
1999-2011	Dental Clinical Pathology Graduate Course (course master)
1999-2002	UAB Surgery Basic Science Course
2001-2014	UASOM Scholar's Week
2003-2015	Heme/Onc Fellows' Didactic Courses
2003-2015	Pediatric Heme/Onc Fellows' Conference
2008-2020	Special Topics, UASOM

MAJOR LECTURES AND VISITING PROFESSORSHIPS:

1. Review of Hemostasis – Scientific session, AABB National Meeting, Orlando, FL, October 2002.
2. Diagnostic Tests to Evaluate Hemostasis – Scientific session, AABB National Meeting, San Diego, CA, November 2003.
3. Thrombophilia and its Treatment – Scientific sessions parts I and II. ASCLS Annual Meeting. Los Angeles, CA, July 2004.
4. Workshop on Hemostasis (6 hours). Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil, June 2004.
5. Transfusion Safety, International Symposium. AABB National Meeting. Baltimore, MD, October 2004.
6. Photopheresis in Solid Organ Transplantation. Mexican Association of Blood Banks. Queretaro, MX, October 2004.
7. Hemostasis: From Physiology to Pathology. Lee Moffit Cancer Center Pathology Grand Rounds. Tampa, FL, March 2005.
8. Theoretical and Practical Aspects of Photopheresis in Solid Organ Transplantation. American Society for Apheresis, Chicago, IL, April 2005.
9. Stepwise Approach to the Bleeding Patient. ASCP Teleconference. April 2005.
10. Thrombotic Microangiopathies. ASCLS National Meeting. Orlando, FL, July 2005.
11. Update on Oral Anticoagulants. ASCLS National Meeting. Orlando, FL, July 2005.
12. Stump the Stars. ASCP Annual Meeting. Seattle, WA, October 2005.

13. Principles of Transfusion Medicine. Carraway Methodist Medical Center Medicine Grand Rounds. Birmingham, AL, December 2005.
14. TRALI – University of Alabama at Birmingham – Medicine Clinico-Pathologic Conference – August 2006.
15. Applications of Therapeutic Apheresis - Mexican Association of Blood Banks National Meeting. Merida, MX, September 2006.
16. Transfusion Reactions Everyone Should Know About! - University of Alabama at Birmingham – Obstetrics and Gynecology Grand Rounds. October 2006.
17. Use of Fresh Frozen Plasma for Correction of the INR – University of Alabama at Birmingham – Medicine Grand Rounds. October 2006.
18. What is New in Therapeutic Apheresis – ASFA Annual Meeting, Nashville, TN, April 2007.
19. The Transfusion Medicine Physician as a Consultant in the Hospital – AABB Annual Meeting. Anaheim, CA, October 2007.
20. New Evidence for Therapeutic Apheresis - AABB Annual Meeting. Anaheim, CA, October 2007.
21. Challenging Coagulation Cases – Tri-State Pathology Meeting. New Orleans, LA, May 2008.
22. Why More is Less in Transfusion Therapy - Tri-State Pathology Meeting. New Orleans, LA, May 2008.
23. Heparin-induced Thrombocytopenia- Precision Biologic Round Table. Dartmouth, NS, Canada, June 2008.
24. Evidence-Based Transfusion Therapy - Saint Vincent’s East Grand Rounds. Birmingham, AL, July 2008.
25. When and How to Use Plasma and Platelets - Baptist Montgomery Grand Rounds. Montgomery, AL, September 2008.
26. Bleeding Patients – Quest Symposium in Bleeding and Thrombosis. Fairfax, VA, September 2008.
27. Clinical Consultation Leads to Cost-Effective Management of Bleeding Patients – University of Vermont Grand Rounds. Burlington, VT, November 2008.
28. Evidence-Based Red Cell Transfusion – Alabama Academy of Family Physicians Mid-Winter Meeting. Hoover, AL, December 2008.
29. Hospital-and Blood Provider-Driven Blood Management: A Unique and Creative Joint Venture - AABB Audio Conference, Birmingham, AL, December 2008.
30. Laboratory Evaluation of Coagulopathies – Cook Children’s Hospital Grand Rounds. Fort Worth, TX, February 2009.
31. Perinatal Transfusions – University of Alabama at Birmingham – Perinatal Grand Rounds. Birmingham, AL, April 2009.
32. Photopheresis – ASFA Annual Meeting Clinical Rounds. San Diego, CA, May 2009.
33. What We Know and Don’t Know About ECP in 2009 - ILABB Fall Meeting. Lisle, IL, September, 2009

34. Apheresis Support for Transplant Patients – AABB Annual Meeting. New Orleans, LA, October 2009.
35. Will My Bleeding Patient Benefit from a Transfusion? – AABB Annual Meeting. New Orleans, LA, October 2009.
36. How a Large Academic Medical Center Decreased its Dependency on Imported Blood -
37. AABB Annual Meeting. New Orleans, LA, October 2009.
38. Von Willebrand Disease – The Greater New Orleans Coagulation Conference. New Orleans, LA, February, 2010.
39. What is My Role as a Clinical Pathologist in the Evaluation of Patients with Bleeding or Thrombosis? - Columbia University Department of Pathology. New York, NY, February 2010.
40. How Multidisciplinary Collaboration Led to a Reduction in Red Blood Cell Usage by More than 25% in a Tertiary Care Hospital – Executive War College on Lab and Pathology Management. New Orleans, LA, April 2010.
41. Transfusion & Blood Management: Practical Advice on How to Save Blood, Save Dollars and Save Lives – The Dark Report Audio Conference, Birmingham, AL, May 2010.
42. Photopheresis in Solid Organ Transplantation. ASFA Annual Meeting. New Orleans, LA, May 2010.
43. How Do I Communicate, Document and Bill as a TM physician? AABB Annual Meeting – Baltimore, MD, October 2010.
44. The Pathologist as a Consultant. ASCP Annual Meeting – San Francisco, CA, October 2010.
45. Graft-versus-host disease (GVHD). ASFA Webinar series. February 2011.
46. Hospital Experience with Blood Management. American Red Cross Medical Advisory Committee. Washington, DC. May 2011
47. Serious Transfusion Reactions. ASCLS Annual Meeting. Atlanta, GA. July 2011
48. Why and How We Should Be Working on Blood Utilization in Our Hospitals. Vanderbilt University Department of Pathology Laboratory Medicine Grand Rounds. Nashville, TN, October 2011.
49. Apheresis in Cardiac Disorders. ASFA Annual Meeting. Atlanta, GA, April 2012.
50. Photopheresis. World Apheresis Association Meeting. Istanbul, Turkey, September 2012.
51. Managing the Complex Bleeding Patient. AABB Annual Meeting, Boston, MA, October 2012.
52. Apheresis 101. AIDS Clinical Trials Group Annual Meeting, Washington DC, July 2013.
53. Out with the Bad, In with the Good. The 6th Annual Therapeutic Apheresis Academy, Charlottesville, Virginia, September 2013.

54. Photopheresis. The 6th Annual Therapeutic Apheresis Academy, Charlottesville, Virginia, September 2013.
55. Transfusion Medicine Physician Career Development and Networking Dinner. AABB Annual Meeting, Denver, CO, October 2013.
56. Thrombotic Thrombocytopenic Purpura. HEMO 2013, Brasilia, Brazil, November 2013.
57. Isolated Prolonged PTT: What Is the Problem? ASCP Webinar. December 2013.
58. What is Laboratory Management? USCAP Annual Meeting. San Diego, CA, March 2014.
59. Is This Enough Laboratory Medicine Training in Medical School? ASCP Annual Meeting, Tampa, FL, October 2014.
60. Care of the Patient Undergoing Therapeutic Apheresis. HEMO 2014, Florianopolis, Brazil, November 2014.
61. Therapeutic Apheresis: Principles and Indications. HEMO 2014, Florianopolis, Brazil, November 2014.
62. Therapeutic Apheresis: State of the Art. HEMO 2014, Florianopolis, Brazil, November 2014.
63. Bone Marrow Necrosis in Sickle Cell Disease. HEMO 2014, Florianopolis, Brazil, November 2014.
64. Patient Blood Management in the United States. Keynote speaker. First Patient Blood Management Symposium. Frankfurt, Germany, March 2015.
65. Laboratory Medicine is a Team Sport. Play On. Klaus Mayer Lecture Award in Laboratory Medicine. Memorial Sloan Kettering Cancer Center, New York City, NY, May 2015.
66. Apheresis in Thrombotic Microangiopathies. Jornada Chilena de Hematologia e Medicina Transfusional. Santiago, Chile, August 2015.
67. Bone Marrow Necrosis and Fat Embolism Syndrome in Sickle Hemoglobinopathies. AABB Annual Meeting, Anaheim, CA, October 2015.
68. Apheresis in Solid Organ Transplantation. HEMO 2015. Sao Paulo, Brazil, November 2015.
69. Apheresis in Neurologic Diseases. HEMO 2015. Sao Paulo, Brazil, November 2015.
70. Extracorporeal Photopheresis. HEMO 2015. Sao Paulo, Brazil, November 2015.
71. Patient Blood Management. 51st ACLPS Annual Meeting. Birmingham, AL, June 2016.

72. Differential Diagnosis of Thrombotic Microangiopathies. AMMT (Mexican Association of Blood Banks). Leon, Mexico, September 2016
73. Alternatives to Transfusion – Prevention of Risks to the Patient. AMMT (Mexican Association of Blood Banks). Leon, Mexico, September 2016
74. Patient Blood Management Around the World – Initiatives and Opportunities. Society for the Advancement of Blood Management Annual Meeting. Grand Rapids, MI, October 2016.
75. Thrombotic Microangiopathies: Current Treatments and Future Directions. AABB Annual Meeting. Orlando, FL, October 2016.
76. Ask the Expert podcast: Open Anesthesia. November 2016.
77. Blood Components and Blood Derivatives. IARS Annual Meeting. Washington, DC, May 2017.
78. Pre-operative anemia: Detection, Evaluation, Management IARS Annual Meeting. Washington, DC, May 2017.
79. Teaching Initiatives to Reduce Diagnostic Errors. Academy of Clinical Scientists Annual Meeting. Birmingham, AL, May 2017.
80. Promoting Appropriateness of Laboratory Utilization. Pathology Grand-Rounds. Medical College of Georgia. Augusta, GA, September 2017.
81. Patient Blood Management in an Adult Academic Hospital. AABB Annual Meeting. San Diego, CA, October 2017.
82. Does Prophylactic Red Blood Cell Exchange Improve Pregnancy Outcomes in Patients with Sickle Cell Disease? AABB Annual Meeting. Boston, MA, October 2018.
83. Hemostatic and Metabolic Alterations in Therapeutic Apheresis. HEMO 2018. Sao Paulo, Brazil, November 2018.
84. What is Changing in Therapeutic Apheresis? HEMO 2018. Sao Paulo, Brazil, November 2018.
85. Changes in Clinical Practice that Affect the Blood Bank/Transfusion Services. ASCLS Annual Meeting, Charlotte, NC, June 2019.
86. What is New in the ASFA Guidelines. XVII Argentinian Congress of Transfusion Medicine. Buenos Aires, AR, September 2019.
87. Indications for Red Blood Cell Exchange Procedures in Sickle Cell Disease. San Antonio, TX, October 2019.

88. Plasma transfusion versus plasmapheresis: Indications x controversies. HEMO 2019. Rio de Janeiro, Brazil, November 2019.
89. Therapeutic apheresis: Current-state. HEMO 2019. Rio de Janeiro, Brazil, November 2019.
90. Vascular access for therapeutic apheresis. HEMO 2019. Rio de Janeiro, Brazil, November 2019.
91. Setbacks (will) happen: Carry on! Annual Bruce R. Smoller Pathology Resident Research Symposium. UAMS, Little Rock, AK, May 2021 (Virtual).
92. How I Used The Tools That ASFA Gave Me To Give Back. Francis S. Morrison, MD Memorial Lecture. ASFA Annual Meeting, Philadelphia, PA, May 2022.
93. Whole blood: Where are We? HEMO 2022. Sao Paulo, Brazil, October 2022.
94. Lymphocyte collections for CAR-T cell therapy. HEMO 2022. Sao Paulo, Brazil, October 2022.

GRANT SUPPORT:

Past

- | | |
|-----------|---|
| 2001-2005 | Health Services Foundation – General Endowment Fund grant for the development of the UAB Coagulation Service; Principal Investigator. |
| 2009-2013 | Co-investigator, RBC storage age and potentiation of transfusion-related clinicopathology in trauma patients. R01 HL95468. R. Patel, PhD (PI). |
| 2011-2013 | Co-investigator, Prospective, Randomized Optimal Platelet and Plasma Ratios (PROPPR). UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER (HOUSTON). J. Kerby, MD, PhD – UAB PI |

Still ongoing studies, but no longer involved

- 340035.01.01.2021742 - Juno Therapeutics, Inc.
An Open-Label Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- 341078.01.01.2022298- Juno Therapeutics, Inc. -- CC-97540-NHL-001
A Phase 1 MultiCenter Open-Label Study Of CC-97540 CD19-Targeted Nex-t Chimeric Antigen Receptor (CAR) T Cells, in Subjects with Relapsed or Refractory B-CELL NONHODGKIN LYMPHOMA
- 341880.01.01.2022753 - Juno Therapeutics, Inc - CC-98633-MM-001
A Phase 1 Multicenter Open-Label Study Of CC-98633 BCMA-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells in Subjects with Relapsed and/or Refracto
- 343077.01.01.2023409 - Juno Therapeutics, Inc – CC-95266-MM-001

UAB 2049 A Phase 1 Multicenter, Open-Label Study of CC-95266 in Subjects with Relapsed and/or Refractory Multiple Myeloma

345553.01.01.2024758 - Juno Therapeutics, Inc - (PENDING) BB2121-MM-007

UAB2098 An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose (RP2D), Safety and Preliminary Efficacy of BB2121 (IDE-CEL) Combination in Subjects with Relapsed /Refractory Multiple Myeloma

346287.01.01.2025138 – Celgene Corp - CA097-001

UAB2178 A Phase 1 Multicenter, Open label Study of BMS-986403 in Subjects with Relapsed and/or Refractory Chronic Lymphocytic Leukemia CLL or Small Lymphocytic Lymphoma SLL

340593.01.03.2024133.10 - University of Pittsburgh

UAB PI: Julie Kanter

Sickle Cell Disease and Cardiovascular Risk-Red Cell Exchange Trial (SCD-CARRE Trial)

Current

2022-2027

UG3HL157401-01A1 - National Institute of Health / National Heart, Lung, & Blood Institute - Trauma Resuscitation with Group O Whole Blood Or Products (TROOP). Co-Investigator 10% effort PI: Jan Jensen

BIBLIOGRAPHY:

MANUSCRIPTS PUBLISHED:

1. Basta M, Langlois P, **Marques MB**, Fries L, Frank MM. High-dose intravenous immunoglobulin modifies complement-mediated *in vivo* clearance. *Blood* 1989; 74:326-33.
2. **Marques MB**, Weller PF, Parsonnet J, Ransil BJ, Nicholson-Weller A. Phosphatidylinositol-specific phospholipase C: a possible virulence factor of *Staphylococcus aureus*. *J Clin Microbiol* 1989;27:2451-4.
3. **Marques MB**, Weller PF, Nicholson-Weller A. Growth in acidic-media increases production of phosphatidylinositol-specific phospholipase C by *Staphylococcus aureus*. *Curr Microbiol* 1992; 25:125-8.
4. **Marques MB**, Kasper DL, Pangburn MK, Wessels MR. Prevention of C3 deposition is a virulence mechanism of the type III group B *Streptococcus* capsular polysaccharide. *Infect Immun* 1992; 60:3986-93.
5. **Marques MB**, Kasper DL, Shroff A, Michon F, Jennings HJ, Wessels MR. Functional activity of antibodies to the group B polysaccharide of group B *Streptococcus* elicited by a polysaccharide-protein conjugate vaccine. *Infect Immun* 1994;62:1593-9.
6. Dale JB, Washburn RG, **Marques MB**, Wessels MR. Hyaluronate capsule and surface M Protein in resistance to opsonization of group A streptococci. *Infect Immun* 1996; 64:1495-501.
7. Jeff L, **Marques MB**, Brookings ES, Waites KB. Detection of *Kingella kingae* bacteremia and identification of the organism in the clinical laboratory: Experience from two cases. *Clin Microbiol Newsletter* 1997; 19:73-6.

8. **Marques MB**, Brookings E, Moser S, Sonke PB, Waites KB. Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of *Acinetobacter baumannii* and synergistic activities of nine antimicrobial combinations. *Antimicrob Agents Chemother* 1997;41:881-5.
9. **Marques MB**, Waites KB, Mangino JE, Hines BB, Moser SA. Genotypic investigation of multidrug-resistant *Acinetobacter baumannii* infections in a medical intensive care unit. *J Hosp Infect* 1997; 37:125-35.
10. Kilby JM, **Marques MB**, Jaye DL, Tabereaux PB, Reddy VB, Waites KB. The role of bone marrow biopsy and culture versus blood culture in the evaluation of human immunodeficiency virus-infected patients for mycobacterial and fungal infections. *Am J Med* 1998; 104:123-8.
11. Pershad J, Simmons GT, Chung D, Frye T, **Marques MB**. Two pediatric abdominal catastrophes due to strangulated left paraduodenal hernias. *Pediatr Emerg Med* 1998; 14:347-9
12. **Marques MB**, Waites KB, Jaye DL, Kilby JM, and Reddy VVB. Histologic examination of bone marrow core biopsies has limited value in the diagnosis of mycobacterial and fungal infection in AIDS patients. *Ann Diag Path* 2000; 4:1-6.
13. Chandler D, Prchal J, **Marques MB**. A patient with rare prothrombin deficiency. *Clin Hemost Rev* 2000;14:7.
14. **Marques MB**, Carr KD, Brumfield CG, Huang ST. A pregnant patient with sickle cell disease and cefotetan-induced immune hemolysis. *Lab Med* 2000; 31:541-3.
15. **Marques MB**, McDonald JM. Defining/measuring the value of clinical information. *Clin Lead Manag Rev* 2000; 14:275-9.
16. **Marques MB**, Triplett DA. When to suspect hypercoagulability and how to investigate it. *Ann Diag Path* 2001; 5:177-83.
17. **Marques MB**, Huang ST. Patients with thrombotic thrombocytopenic purpura commonly develop metabolic alkalosis during therapeutic plasma exchange. *J Clin Apher* 2001; 16:120-4.
18. **Marques MB**. Testing for genetic predisposition to venous thrombosis. *Med Lab Obser* 2002; 34:8-13.
19. Gruszecki A, Wehrli G, Ragland B, Reddy VB, Nabell L, Garcia-Hernandez A, **Marques MB**. Management of a patient with HIV infection and thrombotic thrombocytopenic purpura-induced anemia and thrombocytopenia. *Am J Hematol* 2002; 69:228-31.
20. Khuu HM, Desmond R, Huang ST, **Marques MB**. Characterization of photopheresis in the management of heart and lung transplant rejection. *J Clin Apher* 2002; 17:27-32.
21. Fritsma G, **Marques MB**. Hemostasis in the core laboratory. *Adv Med Lab Profes* 2002;14:13-17.
22. Ragland B, Reed C, Eiland B, Hudson C, Tichenor P, Fritsma GA, Adler BK, **Marques MB**. Lupus anticoagulant interference on the activated protein C resistance assay. *Am J Clin Path* 2003; 119:66-71.
23. **Marques MB**. Treatment of single factor deficiencies: A case-study approach. *Clin Lab Scien* 2003; 16:120-2.
24. Adams A, Audeh Y, de Luna R, Baker M, **Marques MB**. Laboratory testing for coagulation inhibitors. *Lab Med* 2003;8:584-8.

25. de Luna R, Colley, BJ III, Smith K, Divers S, Rinehart J, **Marques MB**. Scurvy: An often forgotten cause of bleeding. *Am J Hematol* 2003; 73:85-7.
26. Mayfield CM, **Marques MB**. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura. *Med Lab Obs* 2003; 35:10-6.
27. Robert F, Busby E, **Marques MB**, Reynolds RE, Carey DE. Phase II study of docetaxel plus enoxaparin in previously untreated patients with advanced or metastatic non-small cell lung cancer. *Lung Cancer* 2003; 42:237-45.
28. Fritsma G, **Marques MB**. Hemostasis in the core laboratory presents complex challenges but productive solutions. *Adv Admin Lab* 2003; 12:38-45
29. **Marques MB**, Fritsma GA, Long JA, Adler BK. Clinical pathology consultation improves coagulation factor utilization in hospitalized adults. *Am J Clin Path* 2003; 120:938-43.
30. Tichenor PH, **Marques MB**. Clinical history is crucial to guide evaluation of prolonged PTT. *Clin Hemost Rev* 2003; 17:8-9.
31. Miller EJ, **Marques MB**, Simmons GT. Etiology of pulmonary thromboembolism in the absence of commonly recognized risk factors. *Am J Forens Med Path* 2003; 24:329-33.
32. Katz B and **Marques MB**. Point of care testing in oral anticoagulation: What is the point? *Med Lab Obs* 2004; 36:30-5.
33. **Marques MB**, Mayfield CM, Blackall DP. Thrombotic thrombocytopenic purpura. *Am J Clin Path* 2004; 121:S89-96.
34. Blackall DP and **Marques MB**. Hemolytic uremic syndrome. *Am J Clin Path* 2004; 121:S89-96.
35. Fritsma GA and **Marques MB**. The top ten problems in coagulation. *Adv Admin Lab* 2004; 16:22-8.
36. Tuncer HH, Mayfield CM, **Marques MB**. Current diagnosis and management of thrombotic thrombocytopenic purpura: Utility of von-Willebrand factor cleaving protease (ADAMTS 13). *Blood Transfus – Italy* 2005; 3: 32-41.
37. Fritsma GA and **Marques MB**. Thrombosis risk testing in the clinical laboratory. *Lab Med* 2005; 36:115-8.
38. **Marques MB**, Tuncer HH, Divers SG, Baker AC, Harrison DK. Acute transient leukopenia as a sign of TRALI. *Am J Hematol* 2005; 80:90-1.
39. Rauch TM, Reilly S, Lazenby A, **Marques MB**. DIC secondary to metastatic adenocarcinoma. *Hematology* 2005; 40:69-78.
40. Dillmon M, Saag M, Hamza S, Adler BK, **Marques MB**. Unusual thromboses in patients with HIV infection and protein S deficiency. *Aids Res Hum Retrov* 2005; 21:753-6.
41. Friesen TJ, Nolan JS, **Marques MB**, Reilly S. Multiple aneurysms in a 34-year-old man. *Lab Med* 2005; 36:764-6.
42. Brown MR, Fritsma MG, **Marques MB**. Transfusion safety: What has been done, what is still needed? *Med Lab Obs* 2005; 37:20-6.
43. Kankirawatana S, Berkow R, **Marques MB**. A neonate with bleeding and multiple factor deficiencies. *Lab Med* 2006; 37:5-7.

44. Curtis BR, Kaliszewski J, **Marques MB**, Saif MW, Nabell L, Blank J, McFarland JG, Aster R. Severe immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. *Am J Hematol* 2006; 81:193-8.
45. Kirklin JK, Brown RN, Huang ST, Naftel DC, Hubbard SM, Rayburn BK, McGiffin DC, Bourge RB, Benza RL, Tallaj JA, Pinderski LJ, Pamboukian SV, George JF, **Marques MB**. Rejection with hemodynamic compromise: Objective evidence for efficacy of photopheresis. *J Heart Lung Transplant* 2006;25:283-8.
46. Lavelle J, **Marques MB**. Bilateral pulmonary thromboembolism in a 42-year-old woman. *Lab Med* 2006; 37:229-31.
47. Reardon JE, **Marques MB**. Evaluation of thrombocytopenia. *Lab Med* 2006; 37:248-51.
48. **Marques MB**, Tuncer HH. Photopheresis in solid organ transplants. *J Clin Apher* 2006; 17;21:72-7
49. Reardon JE, **Marques MB**. Laboratory evaluation and transfusion support of patients with autoimmune hemolytic anemia. *Am J Clin Path* 2006; 125 Suppl:S71-7.
50. Fabres J, Wehrli G, **Marques MB**, Phillips V, Dimmitt R, Westfall AO, Schelonka RL. Risk factors for and volume of red blood cell transfusions in very low birth weight infants. *Transfusion* 2006; 46:1915-20.
51. Kankirawatana S, Huang ST, Arndt D, **Marques MB**. Refractory thrombocytopenia and positive platelet crossmatches without HLA or platelet-specific antibodies. *Am J Hematol* 2007;82:175-6.
52. Tuncer HH, Oster RA, Huang ST, **Marques MB**. Predictors of response and relapse in a cohort of adults with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: A single-institution experience. *Transfusion* 2007;47:107-14.
53. Ellis TC, Nielsen VG, **Marques MB**, Kirklin JK. Thrombelastographic measures of clot propagation: A comparison of alpha with the maximum rate of thrombus generation. *Blood Coagul Fibrinol* 2007;18:45-8.
54. Szczepiorkowski ZM, Bandarenko N, Kim HC, Linenberger ML, **Marques MB**, Sarode, R, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the apheresis applications committee of the American Society for Apheresis. *J Clin Apher* 2007; 22:106-75
55. Shaz BH, Linenberger ML, Bandarenko N, Winters JL, Kim HC, **Marques MB**, et al. Category IV indications for therapeutic apheresis-ASFA fourth special issue. *J Clin Apher* 2007; 22:175-80.
56. Park YA, **Marques MB**. Teaching medical students the principles of Laboratory Medicine. *Clin Lab Med* 2007; 27:411-24.
57. Kankirawatana S, Huang ST, **Marques MB**. Continuous infusion of calcium gluconate in 5% albumin is safe and prevents most hypocalcemic reactions during therapeutic plasma exchange. *J Clin Apher* 2007; 22:265-9.
58. Cherry T, Reddy VB, **Marques MB**. Transfusion-related acute lung injury: past, present, and future. *Am J Clin Path* 2008; 129:287-97.

59. Taylor L, Fritsma GA, **Marques MB**. Screening with the activated protein C resistance assay yields significant savings when testing a population with low prevalence of factor V Leiden. *Am J Clin Path* 2008; 129:494-9.
60. Steciuk M, **Marques MB**. A new "initial" case of transfusion-related acute lung injury. *Blood* 2008;111:5257-8.
61. Weinberg JA, McGwin G Jr, Griffin RL, Huynh VQ, Cherry SA III, **Marques MB**, Reiff DA, Kerby JD, Rue LW III. Age of transfused blood: An independent predictor of mortality despite universal leukoreduction. *J Trauma* 2008; 65:279-84.
62. Weinberg JA, McGwin G Jr, **Marques MB**, Cherry SA III, Reiff DA, Kerby JD, Rue LW III. Transfusion in the less severely injured: Does age of transfused blood affect outcomes? *J Trauma* 2008; 65:794-8.
63. Davis M, Shell D, **Marques MB**, Fix RJ, Long J. Free flap failure secondary to dual thrombophilia. *Microsurgery* 2009; 29:62-5.
64. Staropoli JF, Stowell CP, Tuncer HH, **Marques MB**. An inquiry into the relationship between ABO blood group and thrombotic thrombocytopenic purpura. *Vox Sang* 2009; 96:344-8.
65. Cook R, **Marques MB**. An Adolescent with a history of menorrhagia. *Lab Med* 2009;40:271-3.
66. Vandromme MJ, McGwin G Jr, **Marques MB**, Kerby JD, Rue LW 3rd, Weinberg JA. Transfusion and pneumonia in the trauma intensive care unit: an examination of the temporal relationship. *J Trauma* 2009;67:97-101.
67. **Marques M**. Thrombotic thrombocytopenic purpura and heparin-induced thrombocytopenia: two unique causes of life-threatening thrombocytopenia. *Clin Lab Med* 2009;29:321-38.
68. Ridings HD, Holt L, Cook R, **Marques MB**. Genetic susceptibility to VTE: a primary care approach. *JAAPA* 2009;22:20-5.
69. Harrison SW, Griffin RL, Kerby JD, **Marques MB**, Rue LW 3rd, Weinberg JA. Blood utilization at a level I trauma center: is this as good as it gets? *Am Surg* 2009;75:693-7; discussion 697-8.
70. Gore EM, Jones BS, **Marques MB**. Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome? *J Clin Apher* 2009;24:209-14.
71. Steciuk M, Tichenor P, **Marques MB**. A simple tool to educate laboratory staff about anticoagulation. *Lab Med* 2009;40:687-90.
72. Park YA, Waldrum MR, **Marques MB**. Platelet count and prothrombin time help distinguish thrombotic thrombocytopenic purpura-hemolytic uremic syndrome from disseminated intravascular coagulation in adults. *Am J Clin Pathol* 2010;133:460-5.
73. Smith BR, Aguero-Rosenfeld M, Anastasi J, Baron B, Berg A, Bock JL, Campbell S, Crookston KP, Fitzgerald R, Fung M, Haspel R, Howe JG, Jhang J, Kamoun M, Koethe S, Krasowski MD, Landry ML, **Marques MB**, et al. Educating medical students in laboratory medicine: a proposed curriculum. *Am J Clin Path* 2010;133:533-42.
74. Szczepiorowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, **Marques MB**, Sarode R, Schwartz J, Weinstein R, Shaz BH; Apheresis Applications Committee of the American Society for Apheresis. Guidelines on the use of therapeutic apheresis in clinical

- practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. *J Clin Apher* 2010;25:83-177.
75. Lima J, Reddy VV, **Marques MB**. Transfusion medicine illustrated. Systemic neutrophilic aggregates in transfusion-related acute lung injury. *Transfusion* 2010;50:1427-8.
 76. Weinberg JA, McGwin G Jr, Vandromme MJ, **Marques MB**, Melton SM, Reiff DA, Kerby JD, Rue LW 3rd. Duration of red cell storage influences mortality after trauma. *J Trauma* 2010;69:1427-31; discussion 1431-2.
 77. **Marques MB**, Schwartz J. Update on extracorporeal photopheresis in heart and lung transplantation. *J Clin Apher* 2011;26:146-51.
 78. **Marques MB**, Anastasi J, Ashwood E, Baron B, Fitzgerald R, Fung M, Krasowski M, Laposata M, Nester T, Rinder HM; Academy of Clinical Laboratory Physicians and Scientists. The clinical pathologist as consultant. *Am J Clin Pathol* 2011;135:11-2.
 79. **Marques MB** and Fritsma GA. Von Willebrand disease laboratory diagnosis: the saga continues. *Am J Clin Pathol* 2011;135:818-20.
 80. Ballard RB and **Marques MB**. Pathology consultation on the laboratory evaluation of thrombophilia. *Am J Clin Pathol* 2012;137:553-60.
 81. Adamski A, Hanna CA, Reddy VB, Litovsky SH, Evans CA, **Marques MB**. Multiorgan failure and bone marrow necrosis in three adults with sickle cell- β^+ -thalassemia. *Am J Hematol* 2012;87:621-4.
 82. Fritsma GA, Dembitzer FR, Randhawa A, **Marques MB**, Van Cott EM, Adcock-Funk D, Peerschke EI. Recommendations for appropriate activated partial thromboplastin time reagent selection and utilization. *Am J Clin Pathol* 2012;137:904-8.
 83. Carson JL, Grossman BJ, Kleinman S, Tinmouth AT, **Marques MB**, Fung MK, Holcomb JB, Illoh O, Kaplan LJ, Katz LM, Rao SV, Roback JD, Shander A, Tobian AA, Weinstein R, Swinton McLaughlin LG, Djulbegovic B; for the Clinical Transfusion Medicine Committee of the AABB Red Blood Cell Transfusion: A Clinical Practice Guideline from the AABB. *Ann Intern Med* 2012;157:49-58.
 84. Caudrillier A, Kessenbrock K, Gilliss BM, Nguyen JX, **Marques MB**, Monestier M, Toy P, Werb Z, Looney MR. Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. *J Clin Invest* 2012;122:2661-71.
 85. Adamski J and **Marques MB**. Massive hemolysis due to Thrombotic Thrombocytopenic Purpura (TTP) in a patient with AIDS. *Transfusion* 2012;52:1408-9.
 86. **Marques MB**, Polhill SR, Waldrum MR, Johnson JE, Timpa J, Patterson A, Salzman D. How we closed the gap between red blood cell utilization and whole blood collections in our institution. *Transfusion* 2012;52:1857-67.
 87. Stapley R, Owusu BY, Brandon A, Cusick M, Rodriguez C, **Marques MB**, Kerby JD, Barnum SR, Weinberg JA, Lancaster Jr JR, Patel RP. Erythrocyte storage increases rates of NO and nitrite scavenging: implications for transfusion-related toxicity. *Biochem J* 2012;446:499-508.
 88. Deal T, Hovinga JAK, **Marques MB**, Adamski J. Novel *ADAMTS13* Mutations in an obstetric patient with Upshaw-Schulman Syndrome. *J Clin Apher*. 2013;28:311-6.

89. Tcherniantchouk O, Laposata M, and **Marques MB**. The isolated prolonged PTT. *Am J Hematol* 2013;88:82-5.
90. Griffin D, Al-Nouri ZL, Muthurajah D, Ross JR, Ballard RB, Terrell DR, Vesely SK, George JN, **Marques MB**. First symptoms in patients with thrombotic thrombocytopenic purpura (TTP): what are they and when do they occur? *Transfusion* 2013;53:235-7.
91. Passiment E, Meisel JL, Fontanesi J, Fritsma G, Aleryani SL, **Marques M**. Decoding laboratory test names: A major challenge to appropriate patient care. *J Gen Inter Med* 2013;28:453-8.
92. Goyal J, Reddy VB, **Marques MB**. Acquired von Willebrand disease associated with a myeloproliferative neoplasm. *Haemophilia* 2013;19:e256-7.
93. Scott J, McCleskey B, Adamski J, and **Marques MB**. Thrombotic thrombocytopenic purpura does not show seasonal variation in Alabama. *Transfusion* 2013;53:1864-5.
94. Goyal J, Adamski J, Lima JO, **Marques MB**. Relapses of thrombotic thrombocytopenic purpura after treatment with rituximab. *J Clin Apher* 2013;28:390-4.
95. Hu X, Patel RP, Weinberg JA, Stapley R, **Marques MB**, Barnum SR. The level of complement activation fragments is higher in red blood cell units than segments. *Transfus Apher Sci* 2013;49:692-3.
96. Sarode R, Bandarenko N, Brecher ME, Kiss JE, **Marques MB**, Szczepiorowski ZM, Winters JL. Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. *J Clin Apher* 2014; 29:148-67.
97. Boone JD, Kim KH, **Marques MB**, Straughn JM. Compliance rates and outcomes associated with a restrictive transfusion policy in gynecologic oncology patients. *Gynecol Oncol* 2014;132:227-30.
98. Oliver JC, Griffin RL, Hannon T, **Marques MB**. The success of our patient blood management program depended on an institution-wide change in transfusion practices. *Transfusion* 2014;54(10 Pt 2):2617-24.
99. Hu X, , Patel RP, Weinberg J, **Marques MB**, Ramos TN, Barnum SR. Membrane attack complex generation increases as a function of time in stored blood. *Transf Med* 2014;24:114-6.
100. Carlo W, Kirklin JK, Pearce FB, **Marques MB**, Adamski J, George JF. Single center experience with extracorporeal photopheresis in pediatric heart transplantation. *J Heart Lung Transpl* 2014; 33:624-8.
101. **Marques MB**, Adamski J. Extracorporeal photopheresis: Technique, established and novel indications. *J Clin Apher* 2014;29:228-34.
102. **Marques MB**, Singh N, Reddy VV. Out with the bad and in with the good; red cell exchange, white cell reduction, and platelet reduction. *J Clin Apher* 2014;29:220-7.
103. Vetter TR, Adhami L, Porterfield J, **Marques MB**. Perceptions about blood transfusion: A survey of surgical patients and their anesthesiologists and surgeons. *Anesth Analg* 2014;118:1301-8.
104. **Marques MB**, Balogun RA. Therapeutic apheresis academy: Beyond borders. *J Clin Apher* 2014;29:189-90.

105. Singh N, Vanlandingham S, Halverson C, **Marques MB**, Tallaj J, Kirklin J, Adamski J. Therapeutic plasma exchange rapidly improves cardiac allograft function in patients with presumed antibody-mediated rejection. *J Clin Apher* 2014;29:316-21.
106. **Marques MB**, Wille KM, Ren Z, Sheth M, McGiffin DC. Successful pulmonary thromboendarterectomy in a patient with sickle cell disease treated with a single pre-operative red cell exchange. *Transfusion* 2014;54:1901-2.
107. Williams LA, Hunter JM, **Marques MB**, Vetter TR. Periprocedural management of patients on anticoagulants. *N Am Clin Lab Med* 2014; 34:595-611.
108. Vetter TR, Short RT, Hawn MT, **Marques MB**. Perioperative management of the patient with a coronary artery stent. *Anesthesiology* 2014;121:1093-8.
109. **Marques MB**, Hickner J, Thompson PJ, Taylor JR. Primary care physicians and the laboratory: now and the future. *Am J Clin Pathol* 2014;142:738-40.
110. Limdi N, Nolin T, Booth S, Centi A, Marques MB, Crowley M, Allon M, Beasley T. Influence of kidney function on risk of supra-therapeutic INR related hemorrhage in warfarin users: A prospective warfarin cohort study. *Am J Kidney Dis* 2015;65:701-9.
111. Dasararaju R, **Marques MB**. Adverse effects of transfusion. *Cancer Control* 2015;22:16-25.
112. Harper V, Oh JW, Stapley R, **Marques MB**, Wilson L, Barnes S, Sun CW, Townes T, Patel RP. Peroxiredoxin-2 recycling is inhibited during erythrocyte storage. *Antioxid Redox Signal* 2015;22:294-307.
113. Novak DJ, Bai Y, Cooke RK, **Marques MB**, et al. on behalf of the PROPPR Study Group. Making thawed universal donor plasma available rapidly for massively bleeding trauma patients: the experience of the PROPPR trial centers. *Transfusion* 2015;55:1331-9.
114. Ravi S, Chacko B, Sawada H, Kramer PA, Johnson MS, Benavides GA, O'Donnell V, **Marques MB**, Darley-Usmar VM. Metabolic plasticity in resting and thrombin activated platelets. *PLoS One* 2015;10:e0123597.
115. Stapley R, Rodriguez C, Oh JY, Honavar J, Brandon A, Wagener BM, **Marques MB**, Weinberg JA, Kerby JD, Pittet JF, Patel RP. Red blood cell washing, nitrite therapy, and antiheme therapies prevent stored red blood cell toxicity after trauma-hemorrhage. *Free Radic Biol Med* 2015;85:207-18
116. Oh JY, Stapley R, Harper V, **Marques MB**, Patel RP. Predicting storage-dependent damage to red blood cells using nitrite oxidation kinetics, peroxiredoxin-2 oxidation, and hemoglobin and free heme measurements. *Transfusion* 2015;55:2967-78.
117. Eichbaum Q, Smid WM, Crookes R, Naim N, Mendrone A Jr, Marques JF Jr, **Marques MB**. Apheresis in developing countries around the world. *J Clin Apher* 2015;30:238-46.
118. Pham HP, **Marques MB**, Williams III LA. Rh immune globulin dosing in the obesity epidemic era. *Arch Path Lab Med* 2015;139:1084.
119. Ravi S, Chacko B, Kramer PA, Sawada H, Johnson MS, Zhi D, **Marques MB**, Darley-Usmar VM. Defining the effects of storage on platelet bioenergetics: The role of increased proton leak. *Biochim Biophys Acta* 2015;1852:2525-34.
120. Ravi S, Johnson MS, Chacko BK, Kramer PA, Sawada H, Locy ML, Wilson LS, Barnes S, **Marques MB**, Darley-Usmar VM. Modification of platelet proteins by 4-hydroxynonenal:

- Potential Mechanisms for inhibition of aggregation and metabolism. *Free Radic Biol Med* 2015; 22;143-53.
121. Gibson B, Williams LA, **Marques MB**, Pham HP. Therapeutic plasma exchange for intractable pruritus secondary to primary sclerosing cholangitis. *J Clin Apher* 2016;31:495-6.
 122. Pham HP, Jiang N, Pan Z, Williams LA 3rd, **Marques MB**. Apheresis research-more abstracts should be published as full manuscripts to provide more evidence for clinical practice guidelines. *J Clin Apher* 2016;31:353-8.
 123. Metjian A, Tanhehco YC, Aqui N, Bhoj VG, Jamensky L, **Marques MB**, Onwuemene O, Pham HP, Arepally GM. The thrombotic microangiopathy Registry of North America: A United States multi-institutional TMA network. *J Clin Apher* 2016;31:448-53.
 124. Williams LA 3rd, **Marques MB**. Pathology Consultation on the diagnosis and treatment of thrombotic microangiopathies (TMAs). *Am J Clin Path* 2016;145:158-65.
 125. Mann SA, McCleskey B, **Marques MB**, Adamski J. Establishing an institutional therapeutic apheresis registry. *J Clin Apher* 2016;31:516-22.
 126. Staley EM, Carruba SS, Manning M, Pham HP, Williams LA 3rd, **Marques MB**, Locke JE, Lorenz RG. Anti-blood group antibodies in intravenous immunoglobulin may complicate interpretation of antibody titers in ABOi transplantation. *Am J Transplant* 2016;16:2483-6.
 127. Okerberg CK, Williams LA 3rd, Kilgore ML, Kim CH, **Marques MB**, Schwartz J, Pham HP. Cryoprecipitate AHF vs. fibrinogen concentrates for fibrinogen replacement in acquired bleeding patients - an economic evaluation. *Vox Sang* 2016;111:292-8.
 128. **Marques MB**. The American Society for Apheresis (ASFA) is pleased to offer a Qualification in Apheresis (QIA) in partnership with The Board of Certification (BOC) of the American Society for Clinical Pathology (ASCP) starting in January of 2016! *Transfus Apher Sci* 2016;54:319-20.
 129. May JE, Sullivan JC, LaVie D, LaVie K, **Marques MB**. Inside out: Bone marrow necrosis and fat embolism complicating sickle- β^+ thalassemia. *Am J Med* 2016;129:e321-e4.
 130. Dunbar N, Raval JS, Johnson A, Abikoff C, Adamski J, Cooling L, Grossman B, Kim HC, **Marques MB**, Morgan S, Schmidt A, Sloan S, Su L, Szczepiorkowski ZM, West FB, Wong E, Schneiderman J. Extracorporeal Photopheresis Practice Patterns: An International Survey by the ASFA ECP Subcommittee. *J Clin Apher* 2017;32:215-23.
 131. Gangaraju R, Reddy VB, **Marques MB**. Fat embolism syndrome secondary to bone marrow necrosis in patients with hemoglobinopathies. *South Med J* 2016;109:549-53.
 132. Williams LA, Absar T, Pham HP, Lorenz RL, **Marques MB**. High percentage of evanescent red cell antibodies in patients with sickle cell disease highlights the need for a national antibody database. *South Med J* 2016;109:588-91.
 133. Pagano MB, Harmon C, Cooling L, Connelly-Smith L, Mann SA, Pham HP, **Marques MB**, Schlueter AJ, Case R, King KE, Cataife G, Wu Y, Wong ECC, Winters JL. Use of hydroxyethyl starch in leukocytapheresis procedures does not increase renal toxicity. *Transfusion* 2016;56:2848-56.
 134. Shander A, Bracey AW, Goodnough LT, Gross I, Hassan NE, Ozawa S, **Marques MB**. Patient Blood Management as Standard of Care. *Anest Analg* 2016;123:1051-3.

135. Hassan NE, Tibi P, **Marques MB**. SABM and A&A: A new collaboration, and home for Blood Management research. *Anest Analg* 2016;123:816-7.
136. Cao W, Pham HP, Williams LA, McDaniel J, Siniard RC, Lorenz RG, **Marques MB**, Zheng XL. Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura. *Haematologica* 2016;101:1319-26.
137. Taylor JR, Thompson PJ, Genzen JR, Hickner J, **Marques MB**. Opportunities to enhance laboratory professionals' role on the diagnostic team. *Lab Med* 2017;48:97-103.
138. Brazelton J, Oster RA, McCleskey B, Fuller J, Adamski J, **Marques MB**. Increased troponin I is associated with fatal outcome in acquired thrombotic thrombocytopenic purpura. *J Clin Apher* 2017;32:311-8.
139. Harrigan M, **Marques MB**, Williams LW. A safe and effective management strategy for blunt cerebrovascular injury: Avoiding unnecessary anticoagulation and eliminating stroke. *J Trauma Acute Care Surg* 2017;82:228.
140. Goodnough LT, **Marques MB**. Zika virus and patient blood management. *Anesth Analg* 2017;124:282-9– Press release at: <http://newswise.com/articles/view/665831/>
141. Hill BC, Hanna CA, Adamski J, Pham HP, **Marques MB**, Williams LA 3rd. Ficin-treated red cells help identify clinically significant alloantibodies masked as reactions of undetermined specificity in gel microtubes. *Lab Med* 2017;48:24-8.
142. Graham T, Peavey DB, Gray T, Patel RP, Wang HE, Pittet JF, Kerby JD, **Marques MB**. Assuring hospital supply of fresh red blood cells for critically ill patients. *Transfusion* 2017;57:1320-1.
143. Bendapudi PK, Hurwitz S, Fry A, **Marques MB**, Waldo SW, Li A, Sun L, Upadhyay V, Hamdan A, Brunner AM, Gansner JM, Viswanathan S, Kaufman RM, Uhl L, Stowell CP, Dzik WH, Makar RS. Derivation and external validation of the PLASMIC score for the rapid assessment of adults with thrombotic microangiopathies: a cohort study. *Lancet Haematol* 2017;4:e157-e64.
144. Bendapudi PK, Upadhyay V, Sun L, **Marques MB**, Makar RS. Clinical scoring systems in thrombotic microangiopathies. *Semin Thromb Hemost* 2017;43:540-8.
145. Zhou Y, Reilly SD, Gangaraju R, Reddy VVB, **Marques MB**. An unusual presentation of thrombotic thrombocytopenic purpura. *Am J Med* 2017;130:e323-e6.
146. Townsley MM, Timpa JG, Davies JE Jr, **Marques MB**. Do institution-level blood utilization and blood management initiatives meaningfully impact transfusion practices in cardiac surgery? *Anesth Analg* 2017;125:731-3.
147. Mann SA, Williams LA 3rd, **Marques MB**, Pham HP. Hospital-acquired anemia due to diagnostic and therapy-related blood loss in inpatients with myasthenia gravis receiving therapeutic plasma exchange. *J Clin Apher* 2018;33:14-20.
148. Simmons SC, Staley EM, Dorn DP, Nails AP, **Marques MB**, Williams LA 3rd, Pham HP. Therapeutic plasma exchange for Hashimoto's encephalopathy. *J Clin Apher* 2018;33:444-6.
149. Staley EM, Simmons SC, Feldman AZ, Lorenz RG, **Marques MB**, Williams LA 3rd, Zheng XL, Pham HP. Management of chronic myeloid leukemia in the setting of pregnancy: when is

- leukocytapheresis appropriate? A case report and review of the literature. *Transfusion* 2018;58:456-60.
150. Simmons SC, Taylor LJ, **Marques MB**, Williams LA 3rd. Rat Poisoning: A challenging diagnosis with clinical and psychological implications. *Lab Med* 2018;49:272-5.
 151. Ipe TS, **Marques MB**. Vascular access for therapeutic plasma exchange. *Transfusion* 2018;58 Suppl 1:580-9.
 152. Wagener BM, Hu PJ, Oh JY, Evans CA, Richter JR, Honavar J, Brandon AP, Creighton J, Stephens SW, Morgan C, Dull RO, **Marques MB**, Kerby JD, Pittet JF, Patel RP. Role of heme in lung bacterial infection after trauma hemorrhage and stored red blood cell transfusion: A preclinical experimental study. *PLoS Med* 2018;15:e1002522.
 153. Gautam R, Oh JY, **Marques MB**, Dluhy RA, Patel RP. Characterization of storage-induced red blood cell hemolysis using Raman spectroscopy. *Lab Med* 2018;49:298-310.
 154. Jones AR, Patel RP, **Marques MB**, Donnelly JP, Griffin RL, Pittet JF, Kerby JD, Stephens SW, DeSantis SM, Hess JR, Wang HE; PROPPR Study Group. Older blood is associated with increased mortality and adverse events in massively transfused trauma patients: Secondary analysis of the PROPPR trial. *Ann Emerg Med* 2019;73:650-61.
 155. Williams III LA, Arnesen C, Gunn C, et al. New subcutaneous PowerFlow port results in cost and time-savings in a busy outpatient apheresis clinic. *J Clin Apher* 2019;34:482-6.
 156. Williams LA 3rd, Sikora J, Richardson C, Rigi M, Boshell N, Palmer L, Dunn S, Slover T, Peavey D, Guillory B, **Marques MB**. Solving the calcium gluconate shortage in real-time: Mistakes made and lessons learned. *J Clin Apher* 2019;34:490-4.
 157. Staley EM, Cao W, Pham HP, Kim CH, Kocher NK, Zheng L, Gangaraju R, Lorenz RG, Williams LA, **Marques MB**, Zheng XL. Clinical factors and biomarkers predicting outcome in patients with immune-mediated thrombotic thrombocytopenic purpura. *Haematologica* 2019;104:166-75.
 158. Watts NL, **Marques MB**, Peavey DB, Innis-Shelton R, Saad A, Stasi AD, Salzman D, Lamb LS Jr, Costa LJ. Mobilization of hematopoietic progenitor cells for autologous transplantation using Pegfilgrastim and plerixafor: Efficacy and cost implications. *Biol Blood Marrow Transplant* 2019;25:233-8.
 159. May JE, **Marques MB**, Reddy VVB, Gangaraju R. Three neglected numbers in the CBC: The RDW, MPV, and NRBC count. *Cleve Clin J Med* 2019;86:167-72.
 160. Gangaraju R, May JE, Williams LA III, Reddy VB, MacLennan P, **Marques MB**. Fat embolism syndrome due to bone marrow necrosis in patients with hemoglobinopathies: A life-threatening complication mimicking thrombotic thrombocytopenic purpura. *Am J Hematol* 2019;94:E64-6.
 161. Youssef M, Arnesen C, Arledge C, Langley C, Sylvester D, Sikora J, **Marques MB**, Long Zheng X, Williams LA 3rd. Validation and cost-effectiveness of an in-house dithiothreitol (DTI) treatment protocol for daratumumab patients in a large tertiary care hospital provides gateway for implementation in smaller community hospitals. *Transfus Apher Sci* 2019;58:152-5.
 162. Tsitsikas DA, May JE, Gangaraju R, Abukar J, Amos RJ, **Marques MB**. Revisiting fat embolism in sickle syndromes: diagnostic and emergency therapeutic measures. *Br J Haematol* 2019;186:e112-e5

163. Williams LA 3rd, Sikora J, Aldrees R, Pham GP, **Marques MB**. Anti-Rh alloimmunization after trauma resuscitation. *Transfus Apher Sci* 2019;58:102652.
164. Sui J, Cao W, Halkidis K, et al. Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura. *Blood Adv* 2019;3:4177-86.
165. Williams LA 3rd, Boshell MN, Adamski J, Pham HP, Guillory B, Sikora J, Lisby S, Lovingood A, Zheng XL, **Marques MB**. Exclusive use of PowerFlow ports may not be appropriate for all patients. *J Clin Apher* 2020;35:66-8.
166. Fei F, **Marques MB**, Staley EM, Williams LA. An automated method for direct antiglobulin testing and the resulting amount of phototherapy used at a large academic medical center. *Lab Med* 2020;51:50-5.
167. Jansen JO, Wang H, Holcomb JB et al. Elicitation of prior probability distributions for a proposed Bayesian randomized clinical trial of whole blood for trauma resuscitation. *Transfusion* 2020;60:498-506.
168. Griffin R, Jansen JO, Bosarge P, **Marques MB**, Kerby J. The association between ABO blood type and mortality among severely injured trauma patients. *Shock* 2020;54:205-8.
169. Oh JY, **Marques MB**, Xu X, Li J, Genschmer K, Gaggar A, Jansen JO, Holcomb JB, JF Pittet, Patel RP. Damage to red blood cells during whole blood storage. *J Trauma Acute Care Surg* 2020;89:344-50.
170. May JE, Siniard RC, **Marques M**. The challenges of diagnosing heparin-induced thrombocytopenia in patients with COVID-19. *Res Pract Thromb Haemost* 2020;4:1066-7.
171. Sui J, Lu R, Halkidis K, Kocher NK, Cao W, **Marques MB**, Zheng XL. Plasma levels of S100A8/A9, histone/DNA complexes, and cell-free DNA predict adverse outcomes of immune thrombotic thrombocytopenic purpura. *J Thromb Haemost* 2021;19:370-9.
172. May JE, McGwin G Jr, Gangaraju R, Paschal R, Weaver K, Lima JLO, **Marques MB**. Questioning the association between ABO type and outcomes in patients with COVID-19. *Ann Hematol* 2021;100:3081-2.
173. Crowe E, DeSantis SM, Bonnette A et al. Whole blood transfusion versus component therapy in trauma resuscitation: a systematic review and meta-analysis. *J Am Coll Emerg Physicians Open* 2020;1:633-41.
174. Godby RC, Kornbrust A, Noubouossie D et al. Adaptable stewardship during a pandemic: a multifaceted approach to sustaining the blood supply for individuals with sickle cell disease. *Int J Lab Hematol* 2021;43:O168-70.
175. Honjo K, Russell RM, Li R et al. Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency. *Cell Rep Med* 2020;2(1):100164. doi: 10.1016/j.xcrm.2020.100164.
176. Godby RC, Raju D, Massicano F, Williams LA, Black B, Dorn D, **Marques MB**. Optimizing factor VIII dosing in obese individuals with haemophilia A. *Blood Coagul Fibrinolysis* 2021 32:528-30.
177. Holcomb JB, Spinella PC, Apalseth TO et al. Civilian walking blood bank emergency preparedness plan. *Transfusion* 2021;61 Suppl 1:S313-25.

178. Uhlich R, Hu P, Yazer M et al. Perception of risk in massive transfusion as it relates to fetal outcomes: A survey of surgeons and nurses at one American trauma center. *Transfusion* 2021;61 Suppl 1:S159-66.
179. Yamamoto T, Bikheth MH, **Marques MB** et al. Initial experimental experience of triple-knockout pig red blood cells as potential sources for transfusion in alloimmunized patients with sickle cell disease. *Transfusion* 2021;61(11):3104-18.
180. May JE, Siniard RC, Taylor LJ, **Marques MB**, Gangaraju R. From activated partial thromboplastin time to anti-factor Xa and back again: The evolution of monitoring unfractionated heparin. *Am J Clin Pathol* 2022;157:321-7.
181. Joubeh S, Lima JLO, Wooten M, **Marques MB**, Singh N. Allergic reaction to psoralen-treated platelets: Real or coincidence? *Transfusion* 2022; 62(3):716-7.
182. Godby RC, May JE, Lima JLO, Singh N, **Marques MB**. Congenital and acquired disorders of primary hemostasis. *Ann Blood* 2022;7:10.
183. Godby RC, Gangaraju R, May JE, Kommalapati A, Paschal R, **Marques MB**. Congenital and acquired disorders of secondary hemostasis. *Ann Blood* 2022;7:11.
184. Noubouossie DF, Zaanona MAI, Costa LJ, Pham HP, **Marques MB**, Di Stasi A. Passenger lymphocyte syndrome and autoimmune hypothyroidism following hematopoietic stem cell transplantation. *Case Reports Immunol* Jun 23;2022:1690489.
185. Gelbard RB, Griffin RL, Reynolds L, Abraham P, Warner J, Hu P, Kerby JD, Uhlich R, **Marques MB**, Jansen JO, Holcomb JB. Over-transfusion with blood for suspected hemorrhagic shock is not associated with worse clinical outcomes. *Transfusion* 2022;62 Suppl 1:S177-84.
186. Tsitsikas DA, Mihalca D, Hall J, May JE, Gangaraju R, **Marques MB**, Scully M. Pitfalls in diagnosing thrombotic thrombocytopenic purpura in sickle cell disease. *J Clin Med* 2022;11(22):6676. doi: 10.3390/jcm11226676.
187. Staley EM, **Marques MB**, Siniard RC, Lima JLO, Singh N. Critical shortages of apheresis procedure kits: Apheresis triage and alternative approaches. *J Clin Apher* 2023;38(1):73-74.
188. Oh JY, **Marques MB**, Xu X, Li J, Genschmer KR, Phillips E, Chimento MF, Mobley J, Gaggari A, Patel RP. Different-sized extracellular vesicles derived from stored red blood cells package diverse cargoes and cause distinct cellular effects. *Transfusion* 2023; 63(3):586-600.
189. Uhlich R, Hu P, Yazer M, Jansen JO, Patrician P, **Marques MB**, et al. The females have spoken: A patient-centered national survey on the administration of emergent transfusions with the potential for future fetal harm. *J Trauma Acute Care Surg* 2023; 94(6):791-7.

BOOK REVIEW

1. Lakey MA, **Marques MB**. Modern Blood Banking and Transfusion Medicine – Fifth Edition. (Book Review). *Lab Medicine* 2005; 36:729.

BOOKS

1. **Marques, MB**, Fritsma, GA. “A Quick Guide to Coagulation Testing”- AACC Press; 2006.
2. **Marques, MB**, Fritsma, MG. “A Quick Guide to Transfusion Medicine”- AACC Press; 2007.

3. Reddy, VBB, **Marques, MB**, Fritsma, GA. "A Quick Guide to Hematology Testing"- AACC Press; 2007.
4. **Marques, MB**, Fritsma, GA. "A Quick Guide to Coagulation Testing – second edition"- AACC Press; 2009.
5. Reddy, VBB, **Marques, MB**, Fritsma, GA. "A Quick Guide to Hematology Testing – second edition"- AACC Press; 2013.
6. Williams, LA, Fritsma, MG, **Marques, MB**. "A Quick Guide to Transfusion Medicine- second edition"- AACC Press; 2014.
7. **Marques, MB**, Fritsma, GA. "A Quick Guide to Hemostasis (former Coagulation Testing) – third edition"- AACC Press; 2015.
8. **Marques MB**, Schwartz Y and Wu YY (editors). "Transfusion Therapy – Clinical Principles and Practices." Fourth edition. AABB Press, 2019.
9. Andrews, J and **Marques MB** (editors). "Transfusion Support for Patients with Sickle Cell Disease" Second edition. AABB Press, 2022.

BOOK CHAPTERS

1. **Marques MB**, Fritsma GA. Hemorrhagic Coagulation Disorders. In: Hematology: Clinical Principles and Applications. 3rd edition. Rodak B, Fritsma G, Doig K (editors), 2007.
2. Fritsma GA, **Marques MB**. Thrombosis Risk Testing. In: Hematology: Clinical Principles and Applications. 3rd edition. Rodak B, Fritsma G, Doig K (editors), 2007.
3. **Marques MB**. Apheresis in Solid Organ Transplantation. In: Apheresis: Principles and Practice. 3rd edition. McLeod B, Weinstein R, Szczepiorkowski ZM, Winters J (editors), AABB Press, 2010.
4. **Marques MB**, Dallas, K, Williams III, LA. Patient Blood Management. In: Transfusion Medicine, Apheresis, and Hemostasis. First edition. Pham HP and Williams III LA (editors), Elsevier, 2017.
5. **Marques MB**, Fritsma GA. Hemostasis and Thrombosis – Laboratory Diagnosis and Treatment. In: Transfusion Medicine, Apheresis, and Hemostasis. First edition. Pham HP and Williams III LA (editors), Elsevier, 2017.
6. Saad A, **Marques MB**, Mineishi S. Donor and graft selection strategy. In: Clinical Manual of Blood and Bone Marrow Transplantation. Abutalib SA and Hari P (editors), Wiley, 2017.
7. Schmidt AE, **Marques MB**. Understanding Advanced Hematologic Testing. In: Hematologic Challenges in the Critically Ill. First edition. Shander A and Corwin HL (editors), Springer, 2018.
8. May JE, **Marques MB**. Therapeutic Apheresis for Hematologic Emergencies. In: Hematologic Challenges in the Critically Ill. First edition. Shander A and Corwin HL (editors), Springer, 2018.

9. Gangaraju R, **Marques MB**. Transfusion Reactions and Adverse Events of Transfusion. In: Transfusion Therapy – Clinical Principles and Practices. Fourth edition. Marques MB, Schwartz Y and Wu YY (editors), AABB Press, 2019.
10. Andrews J, Kanter J, Bartow BB, **Marques MB**. Clinical and Laboratory Infrastructure for Sickle Cell Disease Transfusion Management. In: Transfusion Support for Patients with Sickle Cell Disease. Second edition. Andrews, J and **Marques MB** (editors). AABB Press, 2022.

PUBLISHED ABSTRACTS

1. **Marques MB**, Weller PF, Parsonnet J, Kass EH, Nicholson-Weller A. Phosphatidylinositol-specific phospholipase C: A possible virulence factor of *Staphylococcus aureus*. *Clin Res* 1989;37:566A.
2. **Marques MB**, Rex J, Bennett J, Fries LF. Complement and immunoglobulin G in phagocytosis and killing of *Cryptococcus neoformans* by PMN. Abstracts of the 90th Ann Mtg of the ASM, 1990; abs. F-10, p.420.
3. **Marques MB**, Weller PF, Nicholson-Weller A. Low pH culture media increase production of PIPLC by *S. aureus*. Abstracts of the 91st Gen Meeting of the American Society for Microbiology, 1991; abs. B-24, p.29.
4. **Marques MB**, Kasper DL, Pangburn MK, Wessels MR. Type III capsular polysaccharide regulates C3 binding to group B *Streptococcus*. *Clin Res* 1991;39:272A.
5. **Marques MB**, Wessels MR, Jennings HJ, Kasper DL. Capsular sialic acid inhibits alternative pathway opsonization by cell wall polysaccharide antibodies. Abstracts of the 30th Annual Meeting of the Infectious Diseases Society of America (1992); abs.47.
6. **Marques MB**, Mangino JE, Hines BB, Moser SA, Waites KB. Investigation of an outbreak of multidrug-resistant *Acinetobacter baumannii* in a medical intensive care unit. Abstracts of the 95th General Meeting of the American Society for Microbiology, 1995; abs. L-33, p.115.
7. **Marques MB**, Wang S, Brookings E, Moser S, Waites K. Comparative in vitro susceptibilities and synergistic antimicrobial activities against nosocomial isolates of *Acinetobacter baumannii*. American Society for Microbiology, Southeastern Branch, 1995.
8. **Marques MB**, Jaye D, Kilby JM, Waites KB, Reddy VB. Utility of bone marrow examination versus blood culture for detection of mycobacterial and fungal infections in HIV-positive patients. *Am J Clin Path*. 1996;106:143-4.
9. **Marques MB**, Jaye D, Waites KB, Reddy VB. Histologic diagnosis of mycobacterial and fungal infections in AIDS patients. USCAP 1998 meeting abstract book (Boston, MA).
10. **Marques MB**, Moon PM, Huang ST. Metabolic changes associated with therapeutic plasmapheresis. *J Clin Apher*, 1999; 14:90.
11. Huang ST, **Marques MB**, Moon PM, Hulsey D. Photopheresis in child with low blood volume. *J Clin Apher*, 1999;14:100.

12. Huang ST, Huang Z, **Marques MB**, Prchal JT. Adding methoxy polyethylene glycol to red blood cells coated with crosslinked polyethylene glycol-albumin prevents reaction with naturally occurring antibodies while preserving red cell oxygen carrying capacity. *Transf* 1999;39:80S.
13. Khuu HM, **Marques MB**, Huang Z, Annunziata D, Huang ST. Methoxy-and crosslinked polyethylene glycol binding to red cells is stable and does not affect cell membrane function. *Transf* 1999;39:80S.
14. Khuu HM, Reddy VVB, Reed CE, Tichenor PH, Eiland BM, Hudson CL, **Marques, MB**. Decreased platelet counts in 3/8% sodium citrate due to platelet clumping. *Blood* 1999; 94(10S1):80b (abs#3518).
15. Khuu HM, **Marques MB**, Huang ST. Comparison of treatment characteristics between the UVAR and the XTS photopheresis instruments. *Am J Clin Pathol* 2000;114:306-7.
16. Louro AP, **Marques MB**, Carpenter JT, Reddy VVB. Correlation between morphology and immunophenotype in acute leukemias. *Am J Clin Pathol* 2000;114:307.
17. Khuu HM, **Marques MB**, Huang ST. Clinical and technical predictors of lymphocyte yield for photopheresis. *Transf* 2000;40:23S.
18. Huang ST, Moon P, **Marques MB**. Photopheresis in small child using the UVAR XTS system. *Transf* 2001;41:42S.
19. **Marques MB**, Fritsma G, Adler B. Impact of Clinical Pathology intervention in coagulation factor replacement. *Am J Clin Path* 2002;118:301.
20. Long A, Fritsma GA, **Marques MB**. The cost of single coagulation factor replacement in an adult tertiary care center. *Transfusion* 2002, 42:132S.
21. Fritsma GA, Eiland BM, Hudson CL, Reed CE, Tichenor PH, **Marques MB**. The impact of screening prior to genetic testing for factor V Leiden. *Clin Chem* 2003; 49:A7.
22. Pugh JL, Khuu HM, Huang ST, **Marques MB**. Management of high-titer HLA antibody with plasmapheresis and photopheresis in a heart transplant patient. *J Clin Apher* 2003; 18:83.
23. Huang S, Moon P, **Marques MB**. Change interface ratio to prevent platelet loss in plasma exchange using Fresenius 103 cell separator. *J Clin Apher* 2003; 18:83.
24. Baker A, Huang S, McAllister S, **Marques MB**. Rituximab: An emerging therapy for relapsing or refractory thrombotic thrombocytopenic purpura. *Transfusion* 2003; 43:4A.
25. Dillmon M, Saag M, Hamza S, Adler BK, **Marques MB**. Unusual thromboses in patients with HIV infection and protein S deficiency. *Blood* 2003; 102:114b.
26. Lopes TL, **Marques MB**. Lupus anticoagulant and metastatic lung cancer in women: An unusual association with possible therapeutic implications. *Blood* 2003; 102:118b.
27. Mayfield CA, Fritsma GA, Allison JJ, Prevallet B, Adler BK, **Marques MB**. Thrombosis risk test utilization in an academic center. *Am J Clin Path* 2004;122:466.
28. Rauch TM, **Marques MB**. Superwarfarin poisoning should be considered in patients with vitamin K deficiency unresponsive to therapy. *Am J Clin Path* 2004;122:466.
29. Tuncer HH, **Marques MB**, Huang ST. Experience with vortex ports in establishing vascular access for photopheresis. *J Clin Apheresis*, 2004; 19:26.

30. Tuncer HH, **Marques MB**, Harrison KD, Huang ST. In vitro comparison of access flow rates among permanent subcutaneous port catheters of different diameters. *J Clin Apher* 2004; 19:33.
31. Clary K, Holmes L, Katz B, **Marques MB**, Huang ST. Alternative anticoagulation during photopheresis for patients with heparin-induced thrombocytopenia. *J Clin Apher* 2004; 19: 52-3.
32. Tuncer HH, Oster RA, Huang ST, **Marques MB**. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: retrospective analysis of predictors of outcome. *Transf* 2004 44: S20-030E.
33. Kankirawatana S, Huang ST, Arndt D, **Marques MB**. Platelet refractoriness and positive crossmatch caused by antibodies to platelet factor 4-heparin complexes in a critically ill patient. *Transf* 2004 44: SP356.
34. Clary KD, Vance B, Whitehurst S, Stansell L, Huang ST, **Marques MB**. Transfusion safety issues encountered during blood administration audits in a tertiary care hospital. *Transf* 2004 44:AP35.
35. Huang ST, Huang Z, **Marques MB**. Positive ham test on pegylated red blood cells (RBCs) mimics Paroxysmal Nocturnal Hemoglobinuria (PNH). *Transf* 2004 44:S81-040F.
36. Lakey MA, Boctor FN, Knight CS, **Marques MB**. VWF-cleaving protease activity and inhibitor levels do not predict duration of treatment in TTP and HUS. *J Clin Apher* 2005; 20:7.
37. Kankirawatana S, Huang ST, **Marques MB**. Experience with therapeutic plasma exchange at academic center, 1999-2003. *J Clin Apher* 2005; 20:38-9.
38. Knight CS, Vaphiades MS, **Marques MB**, Lakey MA, Boctor FN. Case report: Autoimmune retinopathy treated with plasmapheresis. *J Clin Apher* 2005; 20:39.
39. Kim B, Tichenor P, Taylor L, Hudson C, **Marques M**. Unsuspected enoxaparin-treated patients may have false positive lupus anticoagulant results. *Am J Clin Path* 2005; 124:467.
40. Oetama B, **Marques MB**. In vitro strength of lupus anticoagulants do not correlate with clinical manifestations. *Am J Clin Path* 2005; 124:468
41. Lakey MA, Arndt D, **Marques MB**. Repeat borderline or negative platelet factor-4 ELISA may yield positive results in patients with clinical suspicion of heparin-induced thrombocytopenia. *Blood* 2005;106:83b.
42. Szczepiorkowski ZM, Bandarenko N, Kim HC, Linenberger ML, Maes L, **Marques MB**, et al. A new approach to assign ASFA categories for therapeutic apheresis indications. *J Clin Apher* 2006; 21:1.
43. Yang Z, de Mattos AM, Boctor FN, Huang ST, **Marques MB**. Effect of plasmapheresis on proteinuria and graft survival in focal segmental glomerulosclerosis post renal transplantation. *J Clin Apher* 2006; 21:7.
44. Park YA, **Marques MB**, Boctor FN. Devic's neuromyelitis optica and clinical response to therapeutic plasmapheresis. *J Clin Apher* 2006; 21:37.
45. Reardon J, Yang Z, Tuncer HH, **Marques, MB**. Seasonal variation of TTP-HUS at a tertiary referral center: 1997-2005. *J Clin Apher* 2006; 21:47.

46. Park YA, Tatum, CH, Reardon JE, Alexander CB, Ho KJ, **Marques MB**. Not all microangiopathic hemolytic anemias are thrombotic thrombocytopenic purpura: A clinicopathologic correlation. *Am J Clin Path* 2006;126:470.
47. Burford HN, Tichenor P, Reardon JE, Reddy VVB, McDaniel SA, **Marques MB**. Prolonged partial thromboplastin times without bleeding in two patients with metastatic melanoma and diffuse melanosis cutis. *Am J Clin Path* 2006;126:470.
48. Teng G, McDonough A, **Marques MB**, Chatham W. Association of thrombocytopenia with antiphospholipid antibodies and fibrinolysis. *Arthritis Rheum* 2006;54:4081.
49. Alexander KA, **Marques MB**. Incidence of TRALI during therapeutic plasma exchange for thrombotic microangiopathies. *J Clin Apher* 2007;22:11.
50. Park YA, Lakey MA, **Marques MB**. Exacerbations of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome predict an infection. *J Clin Apher* 2007;22:13.
51. Huang ST, Huang Z, **Marques MB**. Absence of alloimmunization to D antigen in Rh-negative organ transplant patients receiving Rh-positive red blood cells and/or apheresis platelets. *Transfusion* 2007;47:197A.
52. Cherry III SA, McKenzie MD, Arndt D, **Marques, MB**. Therapeutic plasma exchange prior to re-exposure to heparin in a patient with acute heparin-induced thrombocytopenia. *Transf* 2007;47:53A.
53. Li S, Huang ST, **Marques MB**. Thrombotic thrombocytopenic purpura following hepatitis B vaccination. *Transfusion* 2007;47:199A.
54. Sanders RD, Carroll SH, Jones TA, Arndt D, Dlott JS, **Marques MB**. Is the new IgG enzyme-immunoassay for HIT a solution for our diagnostic dilemma? *Am J Clin Path* 2008;130:491.
55. Dailey V, **Marques MB**, Cherry III SA. Stock platelets may provide appropriate platelet increment for patients with neonatal alloimmune thrombocytopenia. *Transfusion* 2008;48:56A.
56. Lima J, **Marques MB**, Reddy V, Troughton M. Identification of anemia prior to elective cardiovascular surgery, an opportunity to reduce transfusion risk? *Transfusion* 2008;48:78A.
57. Alexander K, **Marques MB**. Prospective review of thrombosis complications following recombinant factor VIIa. *Transfusion* 2008;48:81A.
58. Huang S, Huang Z, Jones CR, **Marques MB**, Selection of low titer anti-A and anti-B apheresis platelets by a rapid method for ABO incompatible platelet transfusion. *Transfusion* 2008;48:256A-7A.
59. Alexander K, **Marques MB**. Thrombotic events in the setting of activated recombinant clotting factor VII use. *Am J Clin Path* 2008;130:651.
60. Lima J, **Marques MB**. Rituximab does not prevent TTP relapses. *J Clin Apher* 2009; 24:63.
61. Nunez A, Gorman E, **Marques MB**, Huang ST, Troughton M. Procedure complications occurring during plasma exchange for cryoglobulinemia. *J Clin Apher* 2009; 24:87.
62. Downie B, Rossman J, **Marques MB**. Development of acquired factor V inhibitor after plasma exchange in a patient with congenital factor V deficiency: A case report. *Transfusion* 2009; 49:161A.

63. Lima J, Ren Z, McGiffin D, Nguyen T, Wille K, **Marques MB**. Successful pulmonary thromboendarterectomy in a patient with sickle cell disease treated with a single pre-operative RBC exchange. *J Clin Apher* 2010; 25:41.
64. Huang S, Huang Z, **Marques MB**. ABO antibody titers of solid organ transplant recipients remain low weeks after therapeutic plasma exchange. *J Clin Apher* 2010; 25:11.
65. Deal TM, Kremer-Hovinga J, George JN, **Marques MB**, Adamski J. Novel ADAMTS-13 mutations in an obstetric patient with Upshaw-Schulman Syndrome. *J Clin Apher* 2011; 26:67.
66. Halverson CB, Vanlandingham SC, **Marques MB**, Adamski J. Evaluation of fibrinogen levels in patients with acute cardiac transplant rejection who receive daily therapeutic plasma exchange. *J Clin Apher* 2011; 26:79.
67. Tichenor PH, Taylor LJ, Marques MB. Why and How Laboratory Professionals can avoid misdiagnosis of thrombophilia in protein C and protein S testing. *Am J Clin Path* 2011; 136:A036.
68. Brazelton JD, Scott J, Adamski J, **Marques MB**. Are elevated cardiac markers associated with increased mortality in patients with thrombotic thrombocytopenia purpura? *J Clin Apher* 2012;27:1.
69. Oliver JC, Griffin RL, **Marques MB**. Can We Predict the Need for PRBC Transfusions Based on Current Utilization? *Transfusion* 2012;52:123A.
70. Oliver JC, Griffin RL, **Marques MB**. The success of blood management programs depends on an institution-wide change in transfusion practices. *Transfusion* 2012;52:123A.
71. Zhou Y, Reddy VB, Reilly SD, Litovsky SH, **Marques MB**. Gastrointestinal ischemia as the initial presentation of thrombotic thrombocytopenic purpura. *Am J Clin Path* 2012;138:A258.
72. Scott J, McCleskey B, Adamski J, Vetter T, **Marques MB**. Does ADAMTS13 inhibitor titer correlate with response to therapeutic plasma exchange in thrombotic thrombocytopenic purpura? *J Clin Apher* 2013; 28:87-8.
73. McCleskey B, Scott J, Adamski J, Vetter T, **Marques MB**. In search of demographic and laboratory characteristics associated with increased risk of exacerbation and relapse in idiopathic thrombotic thrombocytopenic purpura. *J Clin Apher* 2013;28:136-7.
74. Herring S, Gibbs MA, Adamski J, **Marques MB**. Impact of outpatient red cell exchange in an institution patient blood management program (PBM). *Transfusion* 2013;53:60A.
75. Hill B, Hanna CA, Adamski J, **Marques MB**. Ficin-treated cells in ID-MTS gel test identify clinically significant antibodies which may mimic non-specific reactivity. *Transfusion* 2013;53:179A.
76. Dasararaju R, Hanna CA, **Marques MB**, Adamski J. Decreased awareness and delayed treatment of patients with hemoglobinopathy and bone marrow necrosis can be fatal. *Transfusion* 2013;53:192A.
77. Gibson B, Mann SA, Williams L, **Marques MB**. Single-center evaluation of changes in indications of apheresis procedures performed in response to publication of updated guidelines for the use of therapeutic apheresis. *J Clin Apher* 2014;29:6.

78. Hill B, Williams LA, **Marques M**, Moon, P. Frequency of unexpected complications in a high-volume apheresis service. *J Clin Apher* 2014;29:16.
79. Tracht JM, Mann SA, Williams LA, **Marques MB**. Does total plasma exchange for thrombotic microangiopathies affect overall plasma usage in the setting of patient blood management? *J Clin Apher* 2014;29:25-6.
80. Mann SA, McCleskey B, **Marques MB**, Adamski J. A single center therapeutic apheresis registry: capturing 10 years of apheresis data. *J Clin Apher* 2014;29:30.
81. Dasararaju R, Mann S, **Marques M**, Williams L. Seasonal variations in myasthenia gravis patients requiring therapeutic plasma exchange. *J Clin Apher* 2014;29:36.
82. Harrison GP, Mullen M, Vetter TR, Turman R, Tichenor P, Taylor L, **Marques MB**. Clinical Pathology Intervention Improves Rate of Heparin Anticoagulation. *Am J Clin Patbol* 2014;142:719-20.
83. Ping Z, Brooks, KA, **Marques MB**, Williams III LA, Pham HP. Using normal saline as part of replacement fluid in therapeutic plasma exchange procedures – A pilot study. *J Clin Apher* 2015; 30:77-78.
84. Mann S A, Pham H P, Williams III L A, **Marques MB**. Diagnostic blood loss in myasthenia gravis inpatients receiving therapeutic plasma exchange contributes to hospital-acquired anemia. *J Clin Apher* 2015;30:79-80.
85. Pagano MB, Mann SA, Schlueter AJ, Cataife G, Pham HP, Hofmann JC, King KE, Delaney M, **Marques MB**, Cooling LL, Wu Y, Wong E, Winters JL. Use of hydroxyethyl starch in leukocytapheresis procedures does not increase renal toxicity. *J Clin Apher* 2015;30:81-82.
86. Gibson B, Pham HP, **Marques MB**, Williams III LA. Therapeutic plasma exchange (TPE) for intractable pruritus secondary to primary sclerosing cholangitis (PSC). *J Clin Apher* 2015; 30:121.
87. Ping Z, Williams III LA, Pham HP, Taylor L, **Marques MB**. Evaluation of aspirin resistance in LVAD patients using whole blood platelet aggregometry. *Am J Clin Path* 2015.
88. Bendapudi PK, Li A, Hamdan A, Fry A, Uhl L, **Marques MB**, Kaufman R, Stowell C, Dzik W, and Makar RS. Derivation and prospective validation of a predictive score for the rapid diagnosis of thrombotic thrombocytopenic purpura: the PLASMIC score. *Blood* 2014;124:231.
89. **Marques MB**, Davies JE, Gayeski T, Timpa J, Kirklin JK. Impact of patient blood management on RBC transfusions and outcomes in cardiovascular surgery. *Transfusion* 2015;55:15A.
90. Siniard RC, Pham HP, **Marques MB**. Hemoglobin S Change in Patients with Sick Cell Disease Undergoing Chronic Red Cell Exchange for Stroke Prevention. *J Clin Apher* 2016;31:97.
91. Jones AJ, Baldwin X, Raju D. **Marques MB**. Pre-operative Anemia is Common in Cancer Patients and is Associated with Increased Hospital Stays. *Anesth Analg* 2016; 123:3S:17.

92. Pham HP, Cao W, Williams III LA, Ping Z, Feldman AZ, Siniard RC, Lorenz RG, **Marques MB**, Zheng XL. Predictors for 30-day mortality in patients with acquired autoimmune thrombotic thrombocytopenia purpura (TTP): A single center experience. *Transfusion* 2016; 56(Suppl 4): 80A.
93. Siniard RC, Staley EM, Paschal RD, Turnipseed EG, **Marques MB**. ADaM: A Web-Based Algorithm for Anemia Diagnosis and Management. *Transfusion* 2016; 56 (Suppl 4):219A.
91. Siniard RC, Paiste J, **Marques MB**. Opportunities to Decrease the CT Radio beyond the MSBOS. *Transfusion* 2016; 56 (Suppl 4):221A.
92. Pham HP, Cao W, Williams III LA, Feldman AZ, Siniard RC, Lorenz RG, Raju D, **Marques MB**, Zheng X L. Predictors for in-hospital mortality in patients with autoimmune thrombotic thrombocytopenia purpura (TTP): A single center experience. *Blood* 2016, 128(22):3853.
93. Graham T, Peavey DB, Gray T, **Marques MB**. The feasibility and implications of limiting red blood cell transfusions to units less than 35 days old. *Am J Clin Pathol* 2017;147(suppl_2):S150.
94. Siniard R, Burczyk-Brown JJ, Godby K, Erba H, **Marques MB**. Downward Platelet Utilization Trends in Acute Leukemia. *Am J Clin Pathol* 2017;147(suppl_2):S159.
95. Saylor B, Arndt D, **Marques MB**. Testing for Platelet Antibody Does Not Predict Results of Platelet Crossmatching in Platelet-Refractory Patients. *Am J Clin Pathol* 2017;147(suppl_2):177.
96. Duncan V, Williams LA 3rd, **Marques MB**. Usage Pattern of 4-Factor Prothrombin Complex Concentrate in a Tertiary Care Center. *Am J Clin Pathol* 2017;147(suppl_2):179-80.
97. Simmons SC, Staley EM, Dorn D, Nails A, **Marques MB**, Williams III LA, Pham HP. Therapeutic Plasma Exchange for Hashimoto Encephalopathy. *J Clin Apher* 2017;32:
98. Simmons SC, Pham HP, Dorn D, Jefcoat J, Williams III LA, **Marques MB**, Lorenz RG, Zheng XL, Duncan SR. Therapeutic Efficacy of Plasma Exchange for Idiopathic Pulmonary Fibrosis (IPF). *J Clin Apher* 2017;32:
99. Manne A, Williams LA, Pham HP and **Marques MB**. Chronic TPE with concurrent immunosuppressive therapy is a risk for infections due to secondary hypogammaglobulinemia. *J Clin Apher* 2018; 33: 200-201.
100. Fakhari M, Costa LJ, Williams LA, **Marques MB**. Can We Predict the Number of Circulating CD34+ Cells From the Complete Blood Cell Count Before and After Plerixafor in Patients With Lymphoproliferative Disorders? *Am J Clin Path* 2019;152 (Suppl 1):S18–S19.
101. Sui J, Cao W, Abdelgawwad M, Kocher NK, Halkidis K, Guillory BK, Williams LA, **Marques MB**, Zheng XL. Longitudinal Changes of Plasma ADAMTS13 Activity, Antigen, and Autoantibodies in Patients With Immune-Mediated Thrombotic Thrombocytopenic Purpura, *Am J Clin Path* 2019;152 (Suppl 1):S21–S22.

102. Godby RC, Gray T, Christopher H, Williams LA, **Marques MB**. Quality Improvement Initiatives to Improve Transfusion Safety and Efficiency for Patients Receiving Daratumumab. *Blood* 2019; 134 (Supplement_1): 2100.
103. Godby RC, Kornbrust A, Noubouossie D, Lima J, **Marques MB**, Siniard RC. Caring for Patients with Sickle Cell Disease during a Pandemic: Continuing to Provide Automated Red Blood Cell Exchange Transfusions in Difficult Times. Continuing to Provide Automated Red Blood Cell Exchange Transfusions in Difficult Times. *Blood* 2020; 136 (Supplement 1): 25–26.
104. May JE, Martin K, Taylor L, Wallace E, **Marques MB**. A road paved with good intentions: A platelet count-based alert to facilitate diagnosis of heparin-induced thrombocytopenia. *Blood* 2021; 138:756.
105. Bartow BB, Kornbrust A, Lima J, Bryant T, **Marques MB**. The evolution of an Apheresis Service: a partnership with the Blood Bank to serve the underserved. *J Clin Apher* 2022; 37: 163-164.
106. Soltani SJ, **Marques MB**, Staley E, Singh N. Older adults can be successful allogenic hematopoietic progenitor cell donors. *J Clin Apher* 2022; 37:175-176.
107. Nails A, Figge DA, Singh N, **Marques MB**. The volume of red blood cells in the apheresis product correlates with the numbers of hematopoietic progenitor cells. *J Clin Apher* 2022; 37:183-184.
108. Noubouossie, D, **Marques MB**, Siniard RC, Lima Jose. Unusual, non-anaphylactic transfusion reactions associated with severe IgA and IgM deficiencies and anti-IgA. *Am J Clin Path* 2021;156:S18-S19.
109. Stanek C, **Marques MB**, Miller B. Evanesence and antibodies to low incidence antigens puts patients with sickle cell disease at risk. *Transfusion* 2022; 62(S2):48A.
110. Bartow BB, **Marques MB**, Gray T, Siniard RC. No clinically significant hemolysis post-whole blood transfusion at a major level 1 trauma center. *Transfusion* 2022; 62: 13-14A.
111. Hoesley J, Taylor L, **Marques MB**, May JE. Rethinking the gold standard: Real-world performance of the serotonin release assay (SRA) and PF4-dependent P-selectin expression assay (PEA) in the diagnosis of heparin-induced thrombocytopenia (HIT). *Blood* 2022; 140(Supplement 1):1215-1216.

POSTER EXHIBITS

1. **Marques MB**, Weller PF, Parsonnet J, Kass EH, Nicholson-Weller A. Phosphatidylinositol-specific phospholipase C: A possible virulence factor of *Staphylococcus aureus*. Am Assoc Clin Research Meeting, 1989.

2. **Marques MB**, Rex J, Bennett J, Fries LF. Complement and immunoglobulin G in phagocytosis and killing of *Cryptococcus neoformans* by PMN. 90th Annual Meeting of the American Society for Microbiology, 1990.
3. **Marques MB**, Weller PF, Nicholson-Weller A. Low pH culture media increase production of PIPLC by *S. aureus*. 91st Gen Meeting of the American Society for Microbiology, 1991.
4. **Marques MB**, Kasper DL, Pangburn MK, Wessels MR. Type III capsular polysaccharide regulates C3 binding to group B *Streptococcus*. Am Assoc Clin Research Meeting, 1991.
5. **Marques MB**, Mangino JE, Hines BB, Moser SA, Waites KB. Investigation of an outbreak of multidrug-resistant *Acinetobacter baumannii* in a medical intensive care unit. Abstracts of the 95th General Meeting of the American Society for Microbiology, 1995.
6. **Marques MB**, Wang S, Brookings E, Moser S, Waites KB. Comparative in vitro susceptibilities and synergistic antimicrobial activities against nosocomial isolates of *Acinetobacter baumannii*. American Society for Microbiology, Southeastern Branch, 1995.
7. **Marques MB**, Jaye D, Waites KB, Reddy VB. Histologic diagnosis of mycobacterial and fungal infections in AIDS patients. USCAP, 1998.
8. Huang ST, Moon P, **Marques MB**. Photopheresis in small child using the UVAR XTS system. AABB Annual Meeting, 2000.
9. Long A, Fritsma GA, **Marques MB**. The cost of single coagulation factor replacement in an adult tertiary care center. AABB Annual Meeting, 2002.
10. Pugh JL, Khuu HM, Huang ST, **Marques MB**. Management of high titer HLA antibody with plasmapheresis and photopheresis in a heart transplant patient. ASFA Annual Meeting, 2003.
11. Fritsma GA, Eiland BM, Hudson CL, Reed CE, Tichenor PH, **Marques, MB**. The impact of screening prior to genetic testing for factor V Leiden. AACC Annual Meeting, 2003.
12. Clary K, Holmes L, Katz B, **Marques MB**. Alternative anticoagulation during photopheresis for patients with heparin-induced thrombocytopenia. ASFA Annual Meeting, 2004.
13. Kankirawatana S, Huang ST, **Marques MB**. Experience with therapeutic plasma exchange at academic center, 1999-2003. ASFA Annual Meeting, 2005.
14. Knight CS, Vaphiades MS, **Marques MB**, Lakey MA, Boctor FN. Case Report: Autoimmune retinopathy treated with plasmapheresis. ASFA Annual Meeting, 2005.
15. Park YA, **Marques MB**, Boctor FN. Devic's neuromyelitis optica and clinical response to therapeutic plasmapheresis. ASFA Annual Meeting, 2006.
16. Reardon J, Yang Z, Tuncer HH, **Marques, MB**. Seasonal variation of TTP-HUS at a tertiary referral center: 1997-2005. ASFA Annual Meeting, 2006.
17. Huang ST, Huang Z, **Marques MB**. Absence of alloimmunization to D antigen in Rh-negative organ transplant patients receiving Rh-positive red blood cells and/or apheresis platelets. AABB Annual Meeting, 2007.
18. Cherry III SA, McKenzie MD, Arndt D, **Marques, MB**. Therapeutic plasma exchange prior to re-exposure to heparin in a patient with acute heparin-induced thrombocytopenia. AABB Annual Meeting, 2007.

19. Li S, Huang ST, **Marques MB**. Thrombotic thrombocytopenic purpura following hepatitis B vaccination. AABB Annual Meeting, 2007.
20. Dailey V, **Marques MB**, Cherry III SA. Stock platelets may provide appropriate platelet increment for patients with neonatal alloimmune thrombocytopenia. AABB Annual Meeting, 2008.
21. Lima J, **Marques MB**, Reddy V, Troughton M. Identification of anemia prior to elective cardiovascular surgery, an opportunity to reduce transfusion risk? AABB Annual Meeting, Montreal, 2008.
22. Nunez A, Gorman E, **Marques MB**, Huang ST, Troughton M. Procedure complications occurring during plasma exchange for cryoglobulinemia. ASFA Annual Meeting, 2009.
23. Downie B, Rossman J, **Marques MB**. Development of acquired factor V inhibitor after plasma exchange in a patient with congenital factor V deficiency: A case report. AABB Annual Meeting, 2009.
24. Lima J, Ren Z, McGiffin D, Nguyen T, Wille K, **Marques MB**. Successful pulmonary thromboendarterectomy in a patient with sickle cell disease treated with a single pre-operative RBC exchange. ASFA Annual Meeting, 2010.
25. Huang S, Huang Z, **Marques MB**. ABO antibody titers of solid organ transplant recipients remain low weeks after therapeutic plasma exchange. ASFA Annual Meeting, 2010.
26. Tichenor PH, Taylor LJ, Marques MB. Why and How Laboratory Professionals can avoid misdiagnosis of thrombophilia in protein C and protein S testing. ASCP Annual Meeting, 2011.
27. Oliver JC, Griffin RL, **Marques MB**. Can we predict the need for PRBC transfusions based on current utilization? AABB Annual Meeting, 2012.
28. Oliver JC, Griffin RL, **Marques MB**. The success of blood management programs depends on an institution-wide change in transfusion practices. AABB Annual Meeting, 2012.
29. McCleskey B, Scott J, Adamski J, Vetter T, **Marques MB**. In search of demographic and laboratory characteristics associated with increased risk of exacerbation and relapse in idiopathic thrombotic thrombocytopenic purpura. ASFA Annual Meeting, 2013.
30. Herring S, Gibbs MA, Adamski J, **Marques MB**. Impact of outpatient red cell exchange in an institution patient blood management program (PBM). AABB Annual Meeting, 2013.
31. Hill B, Hanna CA, Adamski J, **Marques MB**. Ficin-treated cells in ID-MTS gel test identify clinically significant antibodies which may mimic non-specific reactivity. AABB Annual Meeting, 2013.
32. Dasararaju R, Hanna CA, **Marques MB**, Adamski J. Decreased awareness and delayed treatment of patients with hemoglobinopathy and bone marrow necrosis can be fatal. AABB Annual Meeting, 2013.
33. Hill B, Williams LA, **Marques M**, Moon, P. Frequency of unexpected complications in a high-volume apheresis service. ASFA Annual Meeting, 2014.
34. Tracht JM, Mann SA, Williams LA, **Marques MB**. Does total plasma exchange for thrombotic microangiopathies affect overall plasma usage in the setting of patient blood management? ASFA Annual Meeting, 2014.

35. Mann SA, McCleskey B, **Marques MB**, Adamski J. A single center therapeutic apheresis registry: capturing 10 years of apheresis data. ASFA Annual Meeting, 2014.
36. Dasararaju R, Mann S, **Marques M**, Williams L. Seasonal variations in myasthenia gravis patients requiring therapeutic plasma exchange. ASFA Annual Meeting, 2014.
37. Ping Z, Brooks, KA, **Marques MB**, Williams III LA, Pham HP. Using normal saline as part of replacement fluid in therapeutic plasma exchange procedures – A pilot study. ASFA Annual Meeting, 2015.
38. Mann S A, Pham H P, Williams III L A, **Marques MB**. Diagnostic blood loss in myasthenia gravis inpatients receiving therapeutic plasma exchange contributes to hospital-acquired anemia. ASFA Annual Meeting, 2015.
39. Pagano MB, Mann SA, Schlueter AJ, Cataife G, Pham HP, Hofmann JC, King KE, Delaney M, **Marques MB**, Cooling LL, Wu Y, Wong E, Winters JL. Use of hydroxyethyl starch in leukocytapheresis procedures does not increase renal toxicity. ASFA Annual Meeting, 2015.
40. Gibson B, Pham HP, **Marques MB**, Williams III LA. Therapeutic plasma exchange (TPE) for intractable pruritus secondary to primary sclerosing cholangitis (PSC). ASFA Annual Meeting, 2015.
41. Siniard R, Burczyk-Brown JJ, Godby K, Erba H, Marques MB. Downward Platelet Utilization Trends in Acute Leukemia. ACLPS Annual Meeting, 2016.
42. Siniard RC, Paiste J, **Marques MB**. Opportunities to Decrease the CT Ratio beyond the MSBOS. AABB Annual Meeting, 2016.
43. Simmons SC, Staley EM, Dorn D, Nails A, **Marques MB**, Williams III LA, Pham HP. Therapeutic Plasma Exchange for Hashimoto Encephalopathy. ASFA Annual Meeting, 2017.
44. Bartow BB, Kornbrust A, Lima J, Bryant T, **Marques MB**. The evolution of an Apheresis Service: a partnership with the Blood Bank to serve the underserved. ASFA Annual Meeting, May 2022, Philadelphia, PA.

ORAL PRESENTATIONS

Scientific Papers Presented at National and International Meetings

1. **Marques MB**, Wessels MR, Jennings HJ, Kasper DL. Capsular sialic acid inhibits alternative pathway opsonization by cell wall polysaccharide antibodies. 30th Annual Meeting of the Infectious Diseases Society of America, 1992.
2. **Marques MB**, Jaye D, Kilby JM, Waites KB, Reddy VB. Utility of bone marrow examination versus blood culture for detection of mycobacterial and fungal infections in HIV-positive patients. ACLPS Meeting, 1996.
3. **Marques MB**, Moon PM, Huang ST. Metabolic changes associated with therapeutic plasmapheresis. ASFA Annual Meeting, 1999.
4. Huang ST, **Marques MB**, Moon PM, Hulse D. Photopheresis in child with low blood volume. ASFA Annual Meeting, 1999.

5. **Marques MB.** Utilization of coagulation tests and factors in a university hospital. ACLPS National Meeting, 2000.
6. **Marques MB.** Case Studies in Hypercoagulability. Hematology Grand-Rounds, Porto Alegre, RS, Brazil, 2002.
7. **Marques MB,** Fritsma GA, Adler BK. Impact of Clinical Pathology intervention in coagulation factor replacement. ACLPS National Meeting, 2002.
8. A. Baker, S. Huang, S. McAllister, **Marques MB.** Rituximab: An emerging therapy for relapsing or refractory thrombotic thrombocytopenic purpura. AABB Annual Meeting, 2003.
9. Tuncer HH, **Marques MB,** Huang ST. Experience with Vortex ports in establishing vascular access for photopheresis. ASFA Annual Meeting, 2004.
10. Tuncer HH, **Marques MB,** Harrison KD, Huang ST. In vitro comparison of access flow rates among permanent subcutaneous port catheters of different diameters. ASFA Annual Meeting, 2004.
11. Mayfield CA, Fritsma GA, Allison J, **Marques MB.** Thrombosis risk test utilization in an academic center. ACLPS National Meeting, 2004.
12. Rauch TM, **Marques MB.** Superwarfarin poisoning should be considered in patients with vitamin K deficiency unresponsive to therapy. ACLPS National Meeting, 2004.
13. Kim B, Tichenor P, Taylor L, Hudson C, **Marques M.** Unsuspected enoxaparin-treated patients may have false positive lupus anticoagulant results. ACLPS National Meeting, 2005.
14. Oetama B, **Marques MB.** In vitro strength of lupus anticoagulants do not correlate with clinical manifestations. ACLPS National Meeting, 2005.
15. Szczepiorowski ZM, Bandarenko N, Kim HC, Linenberger ML, Maes L, **Marques MB,** et al. A new approach to assign ASFA categories for therapeutic apheresis indications. ASFA Annual Meeting, 2006.
16. Yang Z, de Mattos AM, Boctor FN, Huang ST, **Marques MB.** Effect of plasmapheresis on proteinuria and graft survival in focal segmental glomerulosclerosis post renal transplantation. ASFA Annual Meeting, 2006.
17. Park YA, Tatum, CH, Reardon JE, Alexander CB, Ho KJ, **Marques MB.** Not all microangiopathic hemolytic anemias are thrombotic thrombocytopenic purpura: A clinicopathologic correlation. ACLPS National Meeting, 2006.
18. Burford HN, Tichenor P, Reardon JE, Reddy VVB, McDaniel SA, **Marques MB.** Prolonged partial thromboplastin times without bleeding in two patients with metastatic melanoma and diffuse melanosis cutis. ACLPS National Meeting, 2006.
19. Alexander KA, **Marques MB.** Incidence of TRALI during therapeutic plasma exchange for thrombotic microangiopathies. ASFA Annual Meeting, 2007.
20. Park YA, Lakey MA, **Marques MB.** Exacerbations of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome predict an infection. ASFA Annual Meeting, 2007.
21. Sanders RD, Carroll SH, Jones TA, Arndt D, Dlott JS, **Marques MB.** Is the new IgG enzyme-immunoassay for HIT a solution for our diagnostic dilemma? ACLPS National Meeting, 2008.

22. Huang S, Huang Z, Jones CR, **Marques MB**, Selection of low titer anti-A and anti-B apheresis platelets by a rapid method for ABO incompatible platelet transfusion. AABB Annual Meeting, 2008.
23. Alexander K, **Marques MB**. Thrombotic events in the setting of activated recombinant clotting factor VII use. ASCP Meeting, 2008.
24. Lima J, **Marques MB**. Rituximab does not prevent TTP relapses. ASFA Annual Meeting, 2009.
25. Sanders RD, Tichenor P, Henderson J, **Marques MB**. Chronic viral disease and acquired hemophilia: An association with prognostic significance? ACLPS Annual Meeting, 2009.
26. Huang S, Huang Z, **Marques MB**. ABO antibody titers of solid organ transplant recipients remain low weeks after therapeutic plasma exchange. ASFA Annual Meeting, 2010.
27. Deal TM, Kremer-Hovinga J, George JN, **Marques MB**, Adamski J. Novel ADAMTS-13 Mutations in an Obstetric Patient with Upshaw-Schulman Syndrome. ASFA Annual Meeting, 2011.
28. Halverson CB, Vanlandingham SC, **Marques MB**, Adamski J. Evaluation of Fibrinogen Levels in Patients with Acute Cardiac Transplant Rejection who Receive Daily Therapeutic Plasma Exchange. ASFA Annual Meeting, 2011.
29. Brazelton JD, Scott J, Adamski J, **Marques MB**. Are elevated cardiac markers associated with increased mortality in patients with thrombotic thrombocytopenia purpura? ASFA Annual Meeting Plenary Session, 2012.
30. Zhou Y, Reddy VB, Reilly SD, Litovsky SH, **Marques MB**. Gastrointestinal ischemia as the initial presentation of thrombotic thrombocytopenic purpura. ACLPS Annual Meeting, 2013 (Yaolin Zhao received a Young Investigator Award).
31. Gibson B, Mann SA, Williams L, **Marques MB**. Single-center evaluation of changes in indications of apheresis procedures performed in response to publication of updated guidelines for the use of therapeutic apheresis. ASFA Annual Meeting, 2014.
32. Harrison GP, Mullen M, Vetter TR, Turman T, Tichenor P, Taylor L, **Marques MB**. Clinical Pathology Intervention Improves Rate of Heparin Anticoagulation. ACLPS Annual Meeting, 2014 (Grant Harrison received a Young Investigator Award).
33. Ping Z, Williams III LA, Pham HP, Taylor L, **Marques MB**. Evaluation of aspirin resistance in LVAD patients using whole blood platelet aggregometry. ACLPS Annual Meeting, 2015.
34. Graham T, Peavey DB, Gray T, **Marques MB**. The Feasibility and Implications of Limiting Red Blood Cell Transfusions to Units Less Than 35 Days Old. ACLPS Annual Meeting, 2016.
35. Saylor B, Arndt D, **Marques MB**. Testing for Platelet Antibody Does Not Predict Results of Platelet Crossmatching in Platelet-Refractory Patients. ACLPS Annual Meeting, 2016.
36. Duncan V, Williams LA 3rd, **Marques MB**. Usage Pattern of 4-Factor Prothrombin Complex Concentrate in a Tertiary Care Center. ACLPS Annual Meeting, 2016.
37. Bartow BB, Marques MB, Gray T, Siniard RC. No clinically significant hemolysis post-whole blood transfusion at a major level 1 trauma center. AABB Annual Meeting (Virtual), October 2022.

Invited Lectures at Local and Regional Courses and Meetings

1. Use of flow cytometry in the investigation of hematologic malignancies. Presented at the Annual Meeting of the Alabama State Society of Clinical Laboratory Scientists, April 1999, Birmingham, AL.
2. Use of FFP and factor concentrates. Presented at the Alabama State Association of Blood Banks, September 2000, Birmingham, AL.
3. When to suspect and how to workup hypercoagulability. Presented at the Fourth Annual Update in Diagnostic Pathology, November 2000, Pine Mountain., GA.
4. When to suspect and how to workup hypercoagulability. Presented at the Brookwood Hospital Medicine Grand Rounds, November 2000, Birmingham, AL.
5. The role of clinical information in coagulation testing. Presented at the Alabama State Society for Clinical Laboratory Sciences, November 2000, Birmingham, AL.
6. What is the role of coagulation testing in stroke care? Presented at the Stroke Center Retreat, UAB, December 2000, Birmingham, AL.
7. Von Willebrand disease. Presented at the Brookwood Hospital Medicine Grand Rounds, April 2001, Birmingham, AL.
8. Heparin-induced thrombocytopenia. Presented at the Carraway Education and Research Day, May 2001, Birmingham, AL.
9. How to set up and “profit” from a coagulation service. Presented at the Tristate Pathology Meeting, May 2001, Perdido Beach, AL.
10. Monitoring anticoagulation therapy. Presented at the Second Birmingham Fall Hemostasis Symposium, October 2002, Birmingham, AL.
11. Transfusion Safety. Presented at the Alabama State Society for Clinical Laboratory Science, May 2005, Birmingham, AL.
12. Thrombotic Microangiopathies: Which one is which? Presented at the Alabama State Society for Clinical Laboratory Science, April 2006, Birmingham, AL.
13. Transfusion Triggers – Alabama State Association of Blood Banks Fall Meeting – November 2007, Birmingham, AL.
14. Pancytopenia. UAB Health System Montgomery: Internal Medicine Teaching Rounds - October 2010, Montgomery, AL.
15. Thrombocytopenia: Causes and Implications. UAB Health System Montgomery: Internal Medicine Grand Rounds, October 2010, Montgomery, AL.
16. Practical Aspects of Apheresis. ASFA Regional Meeting, March 2011, Birmingham, AL.
17. Opening Keynote: Reducing Diagnostic Errors. ASCLS Region III 2016 Triennial Meeting. November, 2016, Birmingham, AL.
18. Patient Blood Management. ASCLS Region III 2016 Triennial Meeting. November, 2016, Birmingham, AL.
19. Therapeutic Plasma Exchange – Fall ILABB meeting, October, 2017, Chicago, IL.

20. How to be a servant leader for our patients. Opening Keynote Speaker for CLS lab management meeting, November, 2017, Birmingham, AL.
21. The crucial role of large and small teams of laboratory professionals. Robert and Jean Adams Foundation 9th Annual Clinical Laboratory Sciences Symposium, 2023, Montgomery, AL

MISCELLANEOUS

Web Site Development (no longer in charge): <https://www.uab.edu/medicine/coag/>

Apps developed in collaboration with the CDC

PTT advisor - <https://itunes.apple.com/us/app/ptt-advisor/id537989131?mt=8>

Anticoagulation Manager - <https://itunes.apple.com/us/app/anticoagulation-manager/id1349838916?mt=8>